sign in sign up
<<
Home , Rubitecan

PROSTATE CANCER HHOOTT SSHHEEEETT US TOO! INTERNATIONAL MARCH / APRIL 2001

US TOO! PARTICIPANTS CRITICAL TO US TOO! LOSES SUCCESS OF 2000/01 PC-SPES SURVEY A FOUNDER BY PAUL ANDERSON • Of 168 responses, 11 embolisms oc- VinceYoung was born in Chicago on Au- I want to thank all of you who partici- curred (6.5%) over a six-month to gust 20, 1916, the fourth of six children pated in the Us Too! 2000/01 PC-SPES four-year period (8 leg surface veins, of Edwin and Agnes Young. Growing up Survey. It involved those of us who have 1 leg deep vein, 1 foot, 1 lung). 5 on Chicago’s South Side, he was a gradu- been taking PC-SPES from six months were carried over from previous years. ate of Calumet High School. to over four years. We had our highest 10 of the 11 have resumed taking PC number of participants in three years. SPES after treatment. A good-natured perfectionist whose fam- • When rating quality of life (10 best, 1 ily construction company built and re- As you read over the results, should you worst), 71% indicated levels of 7 and habbed Chicago Public Schools from the have questions relating to interpretation, higher. 20% recorded levels of 10. 1930s to the 1960s, and then did the same content, or questions relating specifically at the University of Chicago Hospitals to your stage of PC, please give me a call • The age of 78% of respondents was in the 60 to 79 year range. died on December 23, 2000. He had suf- at (1-888-784-0399) and we’ll be happy fered a heart attack the week before. to clarify it for you. If you received a TABLE 1 survey and didn’t fill it out and return it PSA AFTER 6 MONTHS TO 4 YEARS toUs Too! this year, please endeavor to participate next year. The more people PSA RESPONDENTS % OF TOTAL we have reporting, the more meaningful Below 1 46 35.0% the survey will become, and we will all Below 2 21 13.5% benefit from it. Below 3 6 4.0% 3 to 4 15 11.0% RESULTS OF THE 5 to 9 19 13.5% US TOO! 2000/01 PC-SPES SURVEY 10 to 20 10 6.0% SUMMARY 21 to 30 0 0.0% Surveys received 168 31 to 40 4 3.0% Surveys recorded 137 Over 41 16 13.0% Surveys not recorded 31 137 100.0% (Incomplete, erratic dosage, etc.) 49% below 2 • 128 (93%) Positive experience (PSA TABLE 2 PSA at Diagnosis reduced or stable). VINCENT EDWIN YOUNG • 9 (7%) Negative experience (PSA re- PSA RESPONDENTS % OF TOTAL 1916 - 2000 duced and then rose over time). 0 to 4 15 13.0% • 67 (49%) had PSA readings below 2 5 to 9 41 32.0% He became a skilled carpenter early in 10 to 19 25 20.5% his career, joining his father and two of after taking PC SPES 6 months to 4 20 to 29 7 6.0% years. his brothers during the 1930s in Young 30 to 49 9 5.0% and Sons Construction Company. In later • When first diagnosed with prostate 50 to 99 9 6.0% years he headed the company, retiring in cancer before any treatment 52 (43%) 100+ 10 7.0% 1996 after almost 60 years. Vince super- had PSA levels below 10. 200+ 3 2.5% vised or helped build intricate projects at 300+ 2 1.5% Chicago Vocational and Dunbar High • 35 (27%) followed watchful waiting 400 to 600 3 2.5% (no treatment) before taking PC SPES. Schools, doctors’ offices and operating 700 to 1,000 3 2.5% rooms at the University of Chicago, and • The two primary side effects when tak- Over 1,000 2 1.5% the entranceway to the U. of C.’s Mitchell ing PC SPES were gynomastia (ten- 129 100.0% Hospital during his career. The long hours der and enlarged breasts) and reduc- 43% below 10 tion in libido. (Continued on Page 9) (Continued on Page 10) US TOO! INTERNATIONAL VISIT US ON THE INTERNET AT WWW.USTOO.ORG 3) Androgen Suppression Plus Radiation 24) Plus Estramustine in CLINICAL TRIALS Therapy in Treating Patients With Treating Patients With Metastatic Prostate Cancer Prostate Cancer Us Too! has agreements with two of the 4) in Treating Patients 25)EF5 Prior to Surgery or Biopsy in internet’s leading clinical trials databases: With Stage IV Prostate Cancer That Patients With Breast, Prostate, or VeritasMedicine (www.veritasmedicine.com) Has Not Responded to Previous Cervical Cancer or High Grade Soft and HopeLink (www.hopelink.com). A recent Hormone Therapy Tissue Sarcoma search found the following clinical trials. 5) Brachytherapy in Treating Patients 26)Effect of Androgen Suppression on With Recurrent Prostate Cancer Bone Loss in Patients With or Without To learn more about the trials listed here, 6) Broxuridine Plus Surgery in Treating Bone Metastases Secondary to Prostate including detailed information about the Patients With Stage I or Stage II Cancer treatment protocol used, and specific contact Prostate Cancer 27)Estramustine, , and information for enrollment, simply visit the 7) Calcitriol in Treating Patients With in Treating Patients With Us Too! website (www.ustoo.org) and click Prostate Cancer Prostate Cancer That Has Not on the appropriate clinical trials banner. 8) in Treating Patients With Responded to Hormone Therapy Metastatic Prostate Cancer That Has 28)External-Beam Radiation Therapy Plus KEEP THIS LIST AS A REFERENCE. Not Responded to Hormone Therapy Implanted Radiation Therapy in Updates published in future HotSheets. 9) and Hormone Therapy Treating Patients With Prostate Cancer in Treating Patients With Prostate 29)Gene Therapy in Treating Patients With Cancer Cancer 10)Chemotherapy in Treating Patients 30)Genistein in Treating Patients With With Prostate Cancer Stage III or Stage IV Prostate Cancer 1) A Pharmacokinetic Study of Genistein, 11)Chemotherapy Plus Hormone Therapy 31)Green Tea Extract in Treating Patients a Tyrosine Kinase Inhibitor Versus Androgen Suppression in With Metastatic Prostate Cancer That 2) A Safety and Feasibility Study of Treating Patients With Metastatic or Has Not Responded to Hormone Active Immunotherapy in Patients with Unresectable Prostate Cancer Therapy Metastatic Prostate Carcinoma Using 12)Combination Chemotherapy in 32)Hormone Therapy and Radiation Autologous Dendritic Cells Pulsed Treating Pain in Patients With Therapy in Treating Patients With with Antigen Encoded in Amplified Hormone Refractory Metastatic Prostate Cancer Autologous Tumor RNA Prostate Cancer 33)Hormone Therapy in Treating Men 13)Combination Chemotherapy in With Stage IV Prostate Cancer 34)Hormone Therapy in Treating Patients THE US TOO! PROSTATE CANCER HOT SHEET IS MADE Treating Patients With Advanced POSSIBLE BY AN UNRESTRICTED EDUCATION GRANT FROM Prostate Cancer Who Have Stage I or Stage II Prostate 14)Combination Chemotherapy in Cancer Treating Patients With Prostate Cancer 35)Hormone Therapy in Treating Patients That Has Not Responded to Hormone With Advanced Prostate Cancer THE INFORMATION AND OPINIONS EXPRESSED IN THIS Therapy 36)Hormone Therapy in Treating Patients PUBLICATION ARE NOT ENDORSEMENTS OR RECOMMENDATIONS 15)Combination Chemotherapy Plus With Prostate Cancer FOR ANY MEDICAL TREATMENT, PRODUCT, SERVICE OR COURSE 37)Hormone Therapy in Treating Patients OF ACTION BY US TOO! INTERNATIONAL, INC., ITS OFFICERS Filgrastim in Treating Patients With AND DIRECTORS, OR THE EDITORS OF THIS PUBLICATION. Stage IV Prostate Cancer That Has Not With Rising PSA Levels Following FOR MEDICAL, LEGAL OR OTHER ADVICE, Responded to Hormone Therapy Radiation Therapy for Prostate Cancer PLEASE CONSULT PROFESSIONAL(S) OF YOUR CHOICE. 16)Combination Chemotherapy With 38)Hormone Therapy Plus Radiation US TOO! HEADQUARTERS STAFF Ketoconazole in Treating Patients With Therapy in Treating Patients With JOHN A. PAGE, FHIMSS, EXECUTIVE DIRECTOR / CEO Prostate Cancer JACQUELINE KONIECZKA, OFFICE MANAGER Prostate Cancer DOROTHY WIENCEK, PATIENT INFORMATION COORDINATOR 17)Combination Chemotherapy With or 39)Hormone Therapy Plus Radiation 5003 FAIRVIEW AVENUE Without Peripheral Stem Cell Therapy With or Without Combination DOWNERS GROVE, IL 60515 Chemotherapy in Treating Patients PHONE:(630) 795-1002 / FAX: (630) 795-1602 Transplantation in Treating Patients With Prostate Cancer With Prostate Cancer US TOO! BOARD OF DIRECTORS: 40)Hormone Therapy With or Without HANK PORTERFIELD, CHAIRMAN 18)Combination Hormone Therapy TERRY ROE, VICE CHAIRMAN Followed by Radiation Therapy in and Prednisone in COLONEL JAMES E. WILLIAMS, JR. (RET) SECRETARY Treating Patients With Prostate Cancer Treating Patients Who Have REMBERT R. STOKES, TREASURER Undergone Radical Prostatectomy for JOHN A. PAGE, FHIMSS, EXECUTIVE DIRECTOR / CEO 19)Combination Therapy in Treating Patients With Advanced Prostate Prostate Cancer DIRECTORS: 41)Hormone Therapy With or Without COLONEL JAMES R. ANDERSON, USAF (RET) Cancer That Has Not Responded to JOHN DEBOER, FOUNDER Hormone Therapy Surgery or Radiation Therapy in JOHN CAMPBELL 20)Computer Planned Radiation Therapy TreatingPatients With Prostate Cancer RONALD M. FABRICK, DDS 42)Hydrocortisone Plus RUSS GOULD in Treating Patients With Stage I or CLAUDE S. HARKINS Stage II Prostate Cancer Aminoglutethimide or Ketoconazole in DANIEL M. MOORE, JR. 21)Cyproterone Acetate in Treating Hot Treating Patients With Localized Stage LEW MUSGROVE IV Prostate Cancer REX ZEIGER Flashes Following Surgical or Chemical Castration for Prostate 43)Hyperthermia Plus Radiation Therapy US TOO! INTERNATIONAL, INC. IS INCORPORATED IN THE Cancer in Treating Patients With STATE OF ILLINOIS AND RECOGNIZED AS A 501(C)(3) 22)Diet and PSA Levels in Patients With Nonmetastatic Advanced Prostate NOT-FOR-PROFIT CHARITABLE CORPORATION. Cancer DONATIONS / GIFTS TO US TOO! ARE TAX DEDUCTIBLE. Prostate Cancer 23)Docetaxel in Treating Patients With 44)Leuvectin Followed By Surgery in COPYRIGHT 2001, US TOO! INTERNATIONAL, INC. Stage II or Stage III Prostate Cancer Treating Patients With Stage II or Stage

P. 2 US TOO! PCA HOTSHEET MAR / APR 2001 PROSTATE CANCER PATIENT SUPPORT 1-800-80-US TOO! US TOO! INTERNATIONAL III Prostate Cancer 68)Radiation Therapy With or Without 6. Phase I Randomized Study of Genistein 45)Leuvectin in Treating Patients With Bicalutamide in Treating Patients With for Prevention of Cancer in Patients With Locally Recurrent Prostate Cancer Stage II, Stage III, or Recurrent Prostate No History of Cancer or With Asymptom- 46)Low, Intermediate, or High Dose Cancer atic Early Prostate Cancer or Other Ma- Suramin in Treating Patients With 69)Standard Therapy With or Without lignancy Hormone-Refractory Prostate Cancer Dalteparin in Treating Patients With 7. Phase I Randomized Study of Genistein 47)Mitoxantrone and G-CSF in Treating Advanced Breast, Lung, Colorectal, or in Patients With Stage III or IV Prostate Patients With Metastatic Prostate Prostate Cancer Cancer Cancer 70)SU5416 Compared to Dexamethasone 8. Phase I Study of 3-Dimensional Confor- 48)Mitoxantrone and Prednisone With or in Treating Patients With Progressive mal Radiotherapy in Patients With Locally Without Leflunomide in Treating Prostate Cancer That Has Not Advanced (Stage T2c and T3) Adenocar- Patients With Stage IV Prostate Cancer Responded to Hormone Therapy cinoma of the Prostate 49)Monoclonal Antibody Therapy in 71)Surgery in Treating Patients With 9. Phase I Study of Calcitriol in Patients With Treating Patients With Kidney or Prostate Cancer Prostate Cancer Prostate Cancer 72)Testosterone in Treating Patients With 10. Phase I Study of Docetaxel, Estramustine, 50)Monoclonal Antibody Therapy in Progressive Prostate Cancer That No Mitoxantrone, and Prednisone in Patients Treating Patients With Prostate Cancer Longer Responds to Hormone Therapy with Advanced Prostate Cancer 51)Nitrocamptothecin in Treating Patients 73)Thalidomide for the Treatment of 11. Phase I Study of Doxorubicin/ With Stage IV Prostate Cancer That Hormone-Dependent Prostate Cancer Estramustine in Hormone-Refractory Has Not Responded to Hormone 74)Trastuzumab and Docetaxel in Treating Metastatic Prostate Cancer Therapy Patients Who Have Metastatic Prostate 12. Phase I Study of Estramustine, Docetaxel, 52) and Bryostatin 1 in Treating Cancer That Is Refractory to Hormone and Carboplatin in Patients With Hormone Patients With Metastatic Prostate Therapy Refractory Prostate Cancer Cancer 75)Trastuzumab in Treating Patients With 13. Phase I Study of Lycopene for the 53)Paclitaxel Plus Estramustine in Prostate Cancer Chemoprevention of Prostate Cancer Treating Patients With Metastatic 76)Trastuzumab Plus R115777 in Treating 14. Phase I Study of Monoclonal Antibody Prostate Cancer Patients with Advanced or Metastatic ABX-EGF in Patients With Renal or Pros- 54)Pain Control in Patients With Recurrent Cancer tate Cancer or Metastatic Breast or Prostate Cancer 77)Ultrasound in Treating Patients With 15. Phase I Study of 55)Peripheral Stem Cell Transplantation Recurrent Stage I or Stage II Prostate With Lutetium Texaphyrin in Patients With and White Blood Cell Transfusions in Cancer Locally Recurrent Prostate Adenocarci- Treating Patients With Refractory 78)Vaccine Therapy in Treating Patients noma Metastatic Solid Tumors With Advanced Prostate Cancer 16. Phase I Study of R115777 and 56)PET Scan in Treating Patients With 79)Vaccine Therapy in Treating Patients Trastuzumab (Herceptin) in Patients With Metastatic Prostate Cancer With Metastatic Prostate Cancer Advanced or Metastatic Adenocarcinoma 57)Photodynamic Therapy With Lutetium 80)Vaccine Therapy in Treating Patients 17. Phase I Study of Recombinant Human Texaphyrin in Treating Patients With With Metastatic Prostate Cancer That Interleukin-12 in Refractory Advanced Locally Recurrent Prostate Cancer Has Not Responded to Hormone Stage Ovarian Cancer and Other Abdomi- 58)Prostatectomy Compared With Therapy nal Carcinomatosis Watchful Waiting in Treating Patients 81)Vaccine Therapy Plus QS21 in Treating 18. Phase I Study of Recombinant Prostate With Stage I or Stage II Prostate Cancer Patients With Progressive Prostate Specific Membrane Antigen (rPSMA) 59)PSA Vaccine or Nilutamide to Treat Cancer Pulsed Autologous Dedritic Cells Advanced Prostate Cancer 82) Plus Paclitaxel in Treating (CaPVax) in Patients With Metastatic 60)PSA-Based Vaccine and Radiotherapy Patients With Metastatic Prostate Hormone Refractory Prostate Cancer to Treat Localized Prostate Cancer Cancer That Is Refractory to Hormone 19. Phase I Study of T Cells Activated In Vitro 61)R115777 in Treating Patients With Therapy and Modified with Chimeric Anti-CEA Progressive, Metastatic Prostate Cancer Immunoglobulin T Cell Receptors (Ig That Has Not Responded to Hormone TCR) and Reinfused in Patients with CEA Therapy Expressing Adenocarcinomas 62)Radiation Therapy in Treating Patients 20. Phase I Study of Testosterone in Patients With Bone Metastases From Breast or 1. A 16-Year Randomized Screening Study With Progressive Androgen Independent Prostate Cancer for Prostate, Lung, Colorectal, and Ova- Prostate Cancer 63)Radiation Therapy in Treating Patients rian Cancer - PLCO Trial 21. Phase I Study of the Etanidazole Deriva- With Prostate Cancer 2. Genetic Mapping of Interactive Suscepti- tive EF5 for the Detection of Hypoxia in 64)Radiation Therapy in Treating Patients bility Loci in Patients and Siblings with Patients With Breast, Prostate, or Cervical With Stage I, Stage II, or Stage III Breast, Colon, Lung, or Prostate Cancer Carcinoma or High Grade Soft Tissue Prostate Cancer 3. Genetic Study of Familial Prostate Can- Sarcomas 65)Radiation Therapy Plus Amifostine in cer 22. Phase I Study of Thompson-Friedenreich Treating Patients With Primary Prostate 4. Identification of Men Under Age 55 w/ a [TF(c)]-Keyhole Limpet Hemocyanin Cancer Genetic Predisposition to Prostate Cancer (KLH) Conjugate Plus Adjuvant QS21 in 66)Radiation Therapy With Androgen 5. NCI HIGH PRIORITY CLINICAL Patients with Progressive Prostate Cancer Suppression in Treating Patients With TRIAL — Phase III Randomized Study 23. Phase I/II Dose-Escalation Study of 3- Prostate Cancer of Prostatectomy vs Expectant Observa- Dimensional Conformal Radiotherapy for 67)Radiation Therapy With or Without tion with Palliative Therapy for Stage I/II Stages I-III Adenocarcinoma of the Pros- Antiandrogen Therapy in Treating Prostate Cancer (PIVOT) tate Patients With Prostate Cancer 6. Phase I Randomized Study of Genistein (Continued on Page 15)

US TOO! PCA HOTSHEET MAR / APR 2001 P. 3 US TOO! INTERNATIONAL VISIT US ON THE INTERNET AT WWW.USTOO.ORG

ting a genetic cancer, such as prostate or MNV with PSA doubling time (PSA DT). PROSTATE testicular, relies heavily on families talk- The PSA DT was measured by using PSA CANCER ing to each other.” The study found knowl- values obtained with an ultrasensitive as- edge among men about prostate and tes- say. None of the patients received adjuvant NEWS ticular cancer, two of the most curable endocrine therapy until PSA failure, except forms of the disease, is negligible. one patient who had lymph node metasta- News items contained in the Us Too! sis and gross positive surgical margins. . . . HotSheet are obtained from various news MEN CANNOT IDENTIFY EARLY WARNING . “MNV can be a useful new parameter for sources and edited for inclusion. Where SIGNS OF PROSTATE CANCER prediction of tumor biology after radical available, a point-of-contact and phone A large number of men cannot identify the prostatectomy,”the authors concluded. number/website address is provided. possible early warning signs of prostate “Further study with a larger patient popu- cancer, according to a new poll. Almost lation is needed to elucidate the role of All references to persons, companies, prod- four in 10 could not pinpoint the symp- MNV in predicting the tumor biology of ucts or services are provided for informa- toms of the disease that kills more than prostate cancer.” tion only, and are not endorsements. Read- 10,000 people each year in the UK. The ers are encouraged to conduct their own Mori poll, commissioned by the Prostate ITS YOUR LIFE SO MAKE TIME FOR TESTING research into any person, company, prod- Cancer Charity, also found that almost a (The Record, Bergen County, NJ March uct or service, and consult with their per- quarter of men surveyed admitted they did 06, 2001) Ask upper- or middle-class men sonal physician before deciding upon any not know what the prostate gland did. More why they have not been screened for pros- course of action. than a fifth incorrectly thought that it tate or colorectal cancer, and many will say helped process urine and a similar number they are simply too busy. The response is * * * * * * * * * * * * * * wrongly said it opens and closes the blad- no different for those on the bottom eco- NEW VA HOTLINE FOR AGENT ORANGE der. nomic rung, said Dr. Naipaul Rambaran, a Vietnam veterans now have a new national St. Joseph’s Hospital and Medical Center toll-free helpline to answer their questions TEXAS STUDY TO FOCUS ON PCA physician who performs about 15 free pros- about Agent Orange exposure, health care (NY Times Syndicate March 13, 2001) tate and colorectal screenings a month for and benefits. The new helpline — 800-749- Researchers here hope to enroll 10,000 the poor under a state grant. “We even go 8387 — is part of the continuing efforts of men in an important new study that seeks into homeless shelters,” said Rambaran, the Department of Veterans Affairs (VA) to answer some major lingering questions “and it takes a lot of coaxing to get those to reach America’s 2.3 million Vietnam about prostate cancer, the most common men to be screened. They have all they can veterans. Callers can speak directly to VA cancer to strike males. The goal of the San do just to get through the day, but we still representatives Monday through Friday Antonio-based study is to improve screen- work hard to convince them.” from 8 a.m. to 4 p.m., Central Standard ing and early detection of prostate cancer, Time, or access a 24-hour automated sys- identify new biochemical clues to the dis- SLIGHTLY ELEVATED PSA POINTS tem. They can leave voice mail messages ease and answer questions about the link TO YEARLY TESTING to have information sent to them or listen between diet and prostate cancer, accord- (Fax Watch Inc / www.faxwatch.com) to recordings about exposure to Agent Or- ing to the researchers involved. “Guys are Men with a slightly elevated PSA levels ange, VA benefits, health care and disabil- at risk for this disease; your lifetime risk is should undergo a yearly PSA test, accord- ity compensation. VA now recognizes 10 about one in six,” said Dr. Ian Thompson, ing to research published in the Feb. 15 medical conditions as being associated professor of surgery at the University of issue of Cancer . To determine how often with Agent Orange. It has been linked to a Texas Health Science Center and the lead patients should be rescreened for prostate variety of health problems, ranging from investigator of the study. “Prostate cancer cancer “in view of the need to minimize rare conditions and certain birth defects in has no symptoms. And it appears that early the cost of testing, and to maximize detec- veterans’ offspring to diseases that are detection makes a difference.” tion of early stage prostate carcinoma,” re- somewhat common in middle age, such as searchers conducted a 10-year study of prostate cancer and adult-onset diabetes. VOLUME-WEIGHTED MEAN NUCLEAR 8,595 men. The study participants were VOLUME PREDICTS PSA AILURE IN aged 50 years or older and had PSA levels MEN DON’T TALK TO THEIR ORGAN-CONFINED PROSTATE CANCER of 4.0 ng/ml or less. Tumor marker mea- SONS ABOUT CANCER Volume-weighted mean nuclear volume surement and/or digital rectal examination (2dayuk March 28, 2001) [MNV] is a powerful predictor of PSA fail- (DRE) and/or transrectal ultrasonography Men don’t talk to their sons or siblings ure for patients with clinically organ-con- screening was performed as a first step. In- about cancer because they respect the need fined prostate cancer treated with radical dividuals with abnormal findings under- for “privacy” according to new research. prostatectomy, according to a retrospective went a prostate biopsy. Among men whose Communication between male family prognostic study of 71 patients (median initial PSA levels were lower than 1.0, 1.0- members is “minimal” which is worrying age, 67 years) with T1/ T2 disease. The 1.9 and 2.0 to 4.0 ng/mL, cancer was de- when the cancer has a genetic base. Medi- researchers estimated MNV by utilizing tected in 0.18 percent (8 of 4,526), 1.0 per- cal sociologist Clare Moynihan, who car- biopsy specimens obtained by a stereologi- cent (27 of 2,724) and 3.6 percent (49 of ried out the research, said new ways must cal method. In addition, MNV was com- 1,345), respectively. Among these men be found of getting men to share informa- pared with other preoperative clinical vari- with prostate cancer, 75 percent (six of tion. She added: “This is of major impor- ables. For patients with PSA failure, the eight) were detected by initial PSA levels tance as determining the risk of a man get- investigators determined the correlation of less than 1.0, 56 percent (15 of 27) by lev-

P. 4 US TOO! PCA HOTSHEET MAR / APR 2001 US TOO! INTERNATIONAL VISIT US ON THE INTERNET AT WWW.USTOO.ORG els less than 1.0 to 1.9 and 63 percent (31 detection rate increases steadily during the their shoes and socks a request that many of 49) by levels less than 2.0 to 4.0. Pros- 10 years after the initial screening with little consider unusual for a dermatologist. tate cancer detection rates within three fluctuation, especially in individuals with “Many tell me it’s not necessary, but I tell years following the initial visit were 0.07 initial PSA levels between 2.0-4.0 ng/mL. them to do it anyway because a melanoma percent, 0.24 percent and 1.2 percent in Researchers believe this group of patients can grow anywhere,” said Zouzias, refer- cases with initial PSA levels lower than 1.0, has the highest risk of developing prostate ring to the most deadly skin cancer. “The 1.0 to 1.9 and 2.0 to 4.0 ng/mL, respec- carcinoma in the future. When PSA levels places that people overlook the most are tively. “It is recommended that DRE and are measured during mass screenings for the scalp, the feet, and the toes.” For phy- PSA measurements should be performed prostate carcinoma, approximately 85%- sicians such as Zouzias, who practices in once every three years in individuals with 90% of the participants have PSA levels Wayne, periodic cancer screenings are a initial PSA levels of less than 1.0 ng/mL,” of <4.0 ng/mL. Information regarding the medical imperative that must be done cor- and ... “PSA screening should be per- likelihood of the future development of rectly every time. The risks, as publicized formed once every year for individuals prostate carcinoma and the appropriate fol- by anti-cancer organizations, are simply with initial PSA levels of 1.0 to 4.0 ng/ low-up methods that should be applied to too great. . . . A leading reason patients of- mL,”the researchers concluded. such a large percentage of people is criti- ten cite for failing to get screened is that cal to early detection and successful treat- “their doctors didn’t tell them to get RESEARCHERS DEVELOP ment. Three prior studies have reported tested,”said Barbara Rimer, director of can- EARLY CANCER DETECTOR longitudinal changes in serum PSA levels cer control and population sciences at the (United Press Intn’l March 23, 2001) in men with initial PSA levels <4.0 ng/mL. National Cancer Institute. Just ask Ernest AMES, Iowa — Researchers are develop- However, the follow-up periods for all Carson, 60, a retired Defense Department ing a new biosensor that could someday three studies were relatively short. In ad- analyst who lives in the District of Colum- allow doctors to detect early indicators of dition, the appropriate method of follow- bia. Two years ago, after Carson received cancer with a simple, inexpensive urine up among patients who were not diagnosed a clean bill of health from his annual physi- test. Researchers at the U.S. Department with prostate carcinoma during their first cal, he saw a notice on television for free of Energy’s Ames Laboratory, have cre- visit was not established. prostate cancer screening at Georgetown ated a biosensor technology that works by University’s Lombardi Cancer Center. mounting antibodies (proteins that fight CANCER COUNSELING SERVICES UNDERUSED foreign agents and infection in the body) DESPITE DOCUMENTED BENEFITS BIOMERICA TO INTRODUCE A 10-MINUTE to a gold chip that is then exposed to a urine (AScribe Newswire March 08, 2001) Very DISPOSABLE PSA TEST IN JAPAN sample. Depending on their design, the few cancer patients take advantage of avail- (PR Newswire March 12, 2001) NEW- antibodies bind to disease indicators known able counseling services, despite a large PORT BEACH, CA. — Biomerica, Inc. as adducts. When scientists then apply a body of evidence showing such interven- today announced that the Japanese Minis- laser to the chip at very low temperatures, tions can improve their treatment outcome. try of Health has approved for distribution the adducts, if present, begin to emit light. “Given the quality and quantity of cancer and marketing EZ-PSA(TM), the “This technology essentially could give us support services nationwide, and the posi- Company’s simple and accurate 10-minute an effective way to perform precancer di- tive outcomes of participation shown in the disposable screening test designed to de- agnosis for a range of cancers,” said Pro- research literature, a high priority should tect Prostate Specific Antigen (PSA), an fessor Ryszard Jankowiak, a senior scien- be placed on identifying ways to increase early warning indicator of prostate cancer. tist at Ames. “With advances in genetics patient use of existing services,” say the The approval follows extensive clinical and our increased knowledge about the study’s co-authors Elizabeth G. Eakin, trials conducted on the product in Japan. origin of disease, we now need to exploit Ph.D., and Lisa A. Strycker, M.A., of the The studies were conducted in collabora- that information to screen for disease indi- Oregon Research Institute. They found that tion with the Departments of Urology at cators,” said Marc Porter, a project con- although 68 percent of breast, colon and Dokkyo University School of Medicine tributor and chemistry professor at Iowa prostate cancer patients reported being and Tokyo University, Diai Memorial Hos- State. “This is basically a development to aware of their HMO’s Cancer Counseling pital, and the Company’s marketing part- achieve that goal.” Jankowiak said that Center, only 8 percent used the center. ner. The EZ-PSA product is a simple ten- while the technology is still far from being Ninety percent of prostate cancer patients minute disposable test which doctors can commercially available, he is working to also were aware of a HMO prostate sup- use while the patient is in the office. EZ- design antibodies that detect the beginnings port group, but only 5 percent made use of PSA utilizes an advanced technology that of prostate and breast cancer. these services...... The main reasons makes it as simple to use as a home preg- patients gave for forgoing support services nancy test. The one-step test requires only STUDY OF MASS SCREENING INDICATES were they already had adequate support (32 a drop of whole blood from a finger prick. NEED FOR RDEPEATED TESTING percent), followed by not knowing the sup- The blood is applied to the test device (NewsRx.com March 09, 2001) port services existed (25 percent) and not which will indicate within 10 minutes Prostate carcinoma screening is recom- receiving a recommendation from their whether the patient’s level of PSA is el- mended every three years in men age 50 physician (13 percent). evated. The key to the treatment of PCa is years or older with initial prostate-specific to detect elevated levels of PSA early, when antigen (PSA) levels of <1.0 ng/mL and FOREWARNED, FOREARMED: THE FACTS cure rates are significantly higher. annually for individuals with initial PSA ABOUT CANCER SCREENING levels of 1.0-4.0 ng/mL, according to a (The Record, NJ - March 07, 2001) FOR A DAILY UPDATE SUBSCRIBE TO THE study published in the February 15, 2001, When Dr. Dimitris Zouzias examines his US TOO! PCA NEWS YOU CAN USE issue of Cancer . The prostate carcinoma patients, he always asks them to remove AT WWW.USTOO.ORG

US TOO! PCA HOTSHEET MAR / APR 2001 P. 5 US TOO! INTERNATIONAL VISIT US ON THE INTERNET AT WWW.USTOO.ORG

to take care of the Thursday people. and radiation). Age was unimportant. SURVIVOR We shared a common bond - fighting More and more programs were brought prostate cancer! PROFILE: in. Jay’s cancer was getting better or at least kept at bay anyway. After spending Seven years later some of our members Jay Keleske three years there, his PSA started to rise have rising PSA’s, and must make some to 1300, a very distressing sign. He was advanced treatment decisions. These are by Bill Eickelberg deemed a candidate for 3 clinical trials, very difficult, especially those of us who Us Too! Regional Director, Wisconsin; along with concurrent radiation of the are dating and are with partners that and co-facilitator Southeastern Wiscon- tumor on the spine. Here is a man who, enjoy intimate moments. Many of the sin Regional Cancer Center, Racine, WI. while he was getting treatment, was also advanced treatments will substantially providing such a valuable service for his reduce their libido - but are necessary for Occasionally we find a prostate cancer fellow patients. He wasn’t even aware of life! patient that becomes more than just a all of the good that he was doing. support group member. Someone who In conclusion, I would like to commend just seems to get the itch to do more than It is extremely helpful to have this kind all prostate cancer patients in support attend meetings. Such a person is Jay of success when we are going through groups, for by being there, ready to help Keleske. the patient process, because we do not the newly diagnosed patients with some see the outcome until the treatment is ideas to make better informed treatment I remember Jay in a Cancer support finished. We do however see some decisions. I also know that I receive group 7 years ago, having been through patients that have been successful with strength when I work personally with his first round of treatment with a radical their treatment, and that gives a lot of men who have recently been diagnosed, prostatectomy, then radiation. Lo and encouragement to keep going. and it gives me some hope for the future. behold open heart surgery was then his challenge. Having been a very successful Such is the case with Jay Keleske, being insurance salesman, Jay headed for help the salesman that he is, and a man who with his feelings. I remember him feeling has chosen his priorities in life. He said very depressed but he beat it by to me once, “Don’t bother me during continuing to come to support groups. fishing season, for I will be gone the entire summer enjoying that important Jay’s other life came to be at the VA part of my life.” The other times we can hospital when his prostate cancer started expect Jay to be talking up Us Too! to his to metastasize. As he was being seen as doctors. He is now in his second clinical a patient, he started asking questions trial in cooperation with the Medical about how he could learn more. And College of Wisconsin and the VA overnight a new Us Too! unit started. He Hospital in Milwaukee. Through that was very instrumental in providing those contact and with his burning desire to veterans with prostate information. promote help in the prostate cancer community, he has responded to MCW’s He also had further prostate cancer interest in establishing another chapter. complications, and started a group at Jay Keleske MCW Medical College of Wisconsin. Perhaps Jay’s place here is to be successful in promoting help for cancer I mean not to single out any one person in Here is a man that started off very patients, and serve as an advocate and the group, and hurt the feelings of the example for all of us to promote Us depressed, and came to a prostate cancer other members with this support group for help. After attending Too!’s support group movement. But he acknowledgement ofJay. Certainly, each is also a friend to many. this group, he discovered a better way to one does his/her part for prostate cancer, deal with his disease. A prostate cancer but I do want to make the point that Congratulations Jay! We all thank you group was starting, and a more open, someday some of us will be faced with friendly, humorous climate discovered. for your example on fighting to keep up the challenge of Prostate Cancer recur- the support group activity growing. rence. For those in our group we observe Having had open heart surgery and other many younger men that have been medical challenges, Jay continued to Jay’s last PSA was 1300. We wish him fortunate and not have had the cancer continued success, luck and prayers in fight. After all of his prostate cancer spread. We too, have people who are no treatment, radical prostatectomy, radia- his treatment. We know longer with us, because their cancer cut he WON’T give up. tion, his cancer was discovered again. short their lives. By this time her had become affiliated * * * * * * * * with he Zablocki Veterans Hospital, in Some perspective is necessary in reading Milwaukee, and found that the therapy this article. I too, am faced with a rising SHOW YOUR was helping very much. True to his PSA, and when I started going to Us Too! SUPPORT! salesman form, he started talking about a meetings in Chicago, Joe Palmari used to support group. Ovenight 2 groups were ask why I was there when most of these PCa Awareness stamps formed at the hospital, one to take care of people were substantially older than I are available on-line (Item #448240) at: the Wednesday clinic patients, and one was. (I was 50 when I had my surgery http://shop.usps.com

P. 6 US TOO! PCA HOTSHEET MAR / APR 2001 US TOO! INTERNATIONAL VISIT US ON THE INTERNET AT WWW.USTOO.ORG

and resistant prostate cancer cells to and asthma, this is the first time that it has AACR ANNUAL apoptosis induction (cell death).” The sec- been associated with an effect on prostate ond study, under lead investigator Dr. cancer. The flavonoid compound, which MEETING NEWS Howard Sands of Morrisville, N.C.-based is found in red wine, tea, green vegetables Piedmont Research Center, showed that a and citrus fruit, has been shown to inhibit Many developmenrts in prostate cancer proprietary intravenous formulation of 9- androgen receptors in types of prostate research were presented at the 92nd NC (rubitecan) had “outstanding antitumor cancer that respond to the hormone. Such Annual meeting of the American activity against human melanoma xe- an effect could slow or even stop growth Association for Cancer Research nografts in nude mice. Furthermore, we of the tumour, says the lead author of the (AACR) in New Orleans, March 24-28. now are investigating whether the I.V. ac- study, Dr Nianzeng Xing. The researchers tivity of 9-NC extends to other human tu- believe that non-hormonal treatments for 1. MGI PHARMA PRESENTS FUR- mor xenografts, and how its spectrum of prostate cancer could become increasingly THER DATA ON IROFULVEN’S activity compares to that of oral prep.” important in the future as, despite surgical ANTI-TUMOR ACTIVITY — MGI / 800-353-1075/ www.supergen.com or radiation therapy to suppress androgens, PHARMA, INC. presented preclinical data recurrence is still likely in most men, pos- which serves as the basis for MGI’s plans 3. CaP CURE-FUNDED STUDY sibly due to mutations in the androgen re- to expand the clinical development of SHOWS THAT LOW CONCENTRA- ceptor. irofulven in a variety of cancers. In one TIONS OF HALOFUGINONE ‘IN- presentation, complete regressions of hor- HIBIT HUMAN PROSTATE CAN- 5. BOOSTING BELIEF THAT FOODS mone-refractory human DU-145 prostate CER GROWTH’, SUGGESTING ‘IT FIGHT CANCER (HealthScout March tumors growing in nude mice were re- MAY BECOME A SUCCESSFUL AND 27, 2001 - www.HealthScout.com) What ported when irofulven was used in combi- EFFECTIVE ANTI-CANCER you eat just might ward off cancer. Sev- nation with Taxotere(R) (docetaxel). Com- THERAPY - (PR Newswire March 28, eral food ingredients and synthetic vita- plete regressions were observed in 17 of 2001) NEWTON, Mass. — Collgard mins may prevent cell changes associated 20 animals administered the drugs in com- Biopharmaceuticals Ltd., a privately held with a variety of tumors, report a series of bination, whereas Taxotere alone produced company, announced today that low doses new studies which were presented. So far, no complete regressions and a submaximal of its proprietary lead compound, the evidence indicates that people who eat dose of irofulven produced complete re- Halofuginone, caused a four- to five-fold plenty of fruits and vegetables and only gressions in two of 10 animals. MGI now decrease in human tumor weight and vol- small amounts of animal fat seem to have plans to initiate a Phase 1 clinical trial to ume in SCID mice when administered a lower risk of certain cancers, such as evaluate this promising drug combination orally (in the diet) and via injection. The colon, breast and prostate. Formal studies in cancer patients. Another investigation study was made possible, in part, by an have been mixed on how much difference reported on the activity of irofulven in com- award from CaP CURE. “Halofuginone is a meal plan makes. However, the latest bination with other anti-cancer agents in an extremely potent anti-cancer agent, findings offer yet more evidence that cer- human tumor cell lines and drug-resistant which works by a novel Panstasis(TM) tain nutrients have anti-cancer properties. human tumor xenografts. Irofulven com- mechanism of action,” said Mark Pines, bined with , I inhibi- Ph.D., Volcani Institute, Rehovot, Israel, 6. LUMICYTE ESCALATES ITS tors, , , or carboplatin the lead investigator and founding scien- PURSUIT OF EARLY CANCER DE- exhibited statistically significant synergis- tist of Collgard Biopharmaceuticals. “In TECTION; NEW ALLIANCE DEDI- tic (or greater than additive) anti-tumor this study, we have demonstrated that CATED TO IMPROVE THE LIVES effects. Such activity suggests a basis for Halofuginone, given in low concentrations, OF MILLIONS (PR Newswire March 27, possible new clinical investigations. MGI blocked the synthesis of collagen type I, 2001) FREMONT, Calif. — LumiCyte, PHARMA’s Medical Communications resulting in the reduction of blood vessel Inc. (Fremont, CA) announced that it is Help Line at 1-800-562-5580 / formation to the prostate cancer tumors. amplifying its efforts to enable the early www.mgipharma.com These results suggest that Halofuginone diagnosis of cancer based on the success may become a successful and effective of its early investigations. “We are pleased 2. STUDIES SHOW SUPERGEN’S anti-cancer therapy,” added Dr. Pines, who to see so many presentations (14) at the RUBITECAN HAS ANTI-TUMOR collaborated with Zelig Eshhar, Ph.D., AACR meeting this year involving the ap- ACTIVITY AGAINST MELANOMA, Weizmann Institute of Science, Rehovot, plication of SELDI biochip technology to PROSTATE AND LUNG CANCER. -- Israel. This work consequently garnered the discovery of new protein biomarkers SuperGen Inc. announced that its novel Dr. Pines and his collaborators a second for cancer,” said T. William Hutchens, in- drug compound, rubitecan — which is now CaP CURE award. Collgard ventor of the SELDI technology and CEO in the final stages of Phase III clinical test- Biopharmaceuticals Ltd. / of LumiCyte. “However,” continued ing as an oral therapy against pancreatic www.collgard.com Hutchens, “a much more significant effort cancer — showed anti-tumor activity is needed to help this important pursuit, against melanoma, prostate cancer and 4. FLAVONOID COMPOUND and now is the time.” The genomics revo- lung cancer, in three separate studies. Data COULD PREVENT PROSTATE CAN- lution has resulted in considerable effort from three studies were presented. The first CER (Health Media Ltd March 27, 2001 - to identify genes involved in the predispo- study, under lead investigator Dr. Devasis http://www.health-news.co.uk) The re- sition of certain individuals to various can- Chatterjee of Brown University, Provi- search, carried out by scientists at the Mayo cers. While this work shows great prom- dence, R.I., concluded that raf kinase in- Clinic, Minnesota, was presented. Al- ise, there is an urgent need for routine ac- hibitory protein (RKIP), when added to 9- though quercetin has been studied for the cess to reliable information that signals the NC (rubitecan), plays an integral function past 30 years, and has been proven safe actual onset of cancer. To address this need, “in the sensitization of 9-NC responsive for the treatment of conditions such as gout LumiCyte has developed powerful new

US TOO! PCA HOTSHEET MAR / APR 2001 P. 7 PROSTATE CANCER PATIENT SUPPORT 1-800-80-US TOO! US TOO! INTERNATIONAL

(AACR NEWS - Continued from Page 7) THERAPY — Immunomedics, Inc. re- sional structure of a spot where cancer cells ported an advance made by the Company’s receive growth instructions, a discovery protein BioChip products to help map and scientists in the attachment of iodine-131 that may speed the development of exquis- identify even trace quantities of serum pro- (I-131), a potent therapeutic isotope, to itely precise new treatments. One of the teins that are altered in association with the antibodies. By using a new peptide-based forces that makes cancer grow rampantly early development of cancer. LumiCyte linking method, degradation of I-131 from is a substance called insulin-like growth has designed its BioChips to be used be- the antibody after it is bound to tumor is factor, or IGF. Without this hormone, many yond the laboratory(TM) where immedi- reduced. This has been one of the major cancers will shut down and die. Research- ate clinical utility can be realized. / limitations of using I-131-labeled antibod- ers have long understood the importance www.lumicyte.com ies for cancer therapy. Dr. Gary Griffiths, of IGF but so far have been unable to ex- Executive Director of Chemistry at ploit this knowledge to make new cancer 7. NEW CLINICAL DATA CONFIRM Immunomedics, explained “these new drugs. The obvious strategy is to block the ENDOSTATIN’S PHARMACOLOGI- linkers showed significantly enhanced re- spot that lets IGF get into cells. However, CAL PROFILE IN CANCER PA- tention and improved targeting of the I- this structure, called a receptor, is ex- TIENTS AND EXTEND PRECLINI- 131-labeled antibody in a human lung can- tremely similar to another one that serves CAL RESULTSPRECLINICAL DATA cer growing in mice. This was especially as the entry point for insulin. / DEMONSTRATES ENDOSTATIN IN- impressive with the use of an internalizing www.amgen.com TERACTS SYNERGISTICALLY antibody that targets lung, breast, ovarian, WITH A CURRENT LEADING CHE- and prostate cancers, which we plan to take 11. PROGENICS, CYTOGEN DE- MOTHERAPY DRUG AND MAY EX- into clinical trials,” he added. “Up to now, VELOP PROSTATE TREATMENT — ERT ITS ANTIANGIOGENIC EF — most therapeutic antibodies using I-131 Progenics Pharmaceuticals, Inc. and EntreMed, Inc. released favorable data have required individualized patient dos- Cytogen Corporation have formed a joint from one clinical and two preclinical stud- ing, because the isotope is detached quickly venture to develop a treatment for prostate ies on recombinant human Endostatin, one and distributes differently among patients,” cancer using newly-created human mono- of its three lead product candidates. This Dr. Griffiths said. “By improving retention clonal antibodies. Both the joint venture latest round of data comes from three sepa- in the tumor, we are hopeful that we have — PSMA Development Company LLC — rate studies, which collectively provide developed a more potent yet safer cancer and the successful creation of the human important insights into the behavior of the therapeutic product, although considerably antibodies were announced. The two com- endogenous angiogenesis inhibitor which, more animal and clinical experimentation panies will use XenoMouse(TM) technol- in clinical studies reported last fall, was is needed before it becomes a viable alter- ogy from Abgenix Inc. to create the anti- very well tolerated and demonstrated signs native to our current investigational prod- bodies. The antibodies target prostate-spe- of clinical benefit and biological impact on ucts,” he remarked. / cific membrane antigen (PSMA), a chemi- tumor blood supply. “We are pleased with www.Immunomedics.com cal marker abundantly produced by pros- the Endostatin data presented at this con- tate cancer cells...... The Progenics- ference. The three posters presented today 9. NEW DATA ON PANZEM DEMON- Cytogen joint venture plans to develop contain data that have potential clinical STRATES ACTIVITY AGAINST A three approaches to the use of human impact. Through our internal research ef- WIDE VARIETY OF CANCERS — monoclonal antibodies: by themselves; forts we continue to build a broader un- EntreMed, Inc. released data from a pre- beefed up with anti-cancer toxins; or ra- derstanding of how Endostatin behaves in clinical study of Panzem (2- dio-labeled. Directed to the target tumor, the human body. The latest data bolster Methoxyestradiol), indicating that in ad- the antibodies would sweep out to selec- Endostatin’s potential as a therapeutic can- dition to significantly reducing the size of tively target PSMA-expressing cancer didate for a wide variety of cancer pa- primary tumors, Panzem very effectively cells. Compared to surgery or radiation/ tients,” said Dr. Edward Gubish, inhibited the spread of metastatic disease chemotherapy treatment, a monoclonal EntreMed’s Executive Vice President of in mice. “Panzem demonstrated dose-de- treatment is expected to be much less in- Research and Development. A Phase I pendent antiangiogenic and antitumoral vasive and have comparatively minimal clinical study at University of Wisconsin effects, inhibiting the growth of tumor cells side effects. / www.progenics.com Comprehensive Cancer Center, Madison, and their blood cells. This is significant in WI, demonstrated that the pharmacokinet- that the effects translate across a broad ABOUT AACR: The American ics of Endostatin administered with a daily range of tumor types and include both pri- Association for Cancer Research is a sci- i.v. are linear and very consistent at all mary and metastatic tumor models,” said entific society of over 15,000 laboratory doses. In addition, as the Endostatin circu- Dr. Edward Gubish, EntreMed’s Executive and clinical cancer researchers, was lates through the bloodstream, it undergoes Vice President of Research and Develop- founded in 1907 to facilitate communi- limited degradation. The poster is entitled, ment. The poster, “2-Methoxyestradiol: An cation and dissemination of knowledge “A Phase I and Pharmacokinetic Study of Orally Active Agent in a Broad Range of among scientists and others dedicated to Recombinant Human Endostatin.” ...... Primary and Metastatic Tumor Models,” the cancer problem; to foster research in ABSTRACT INCLUDED: Prostate Spe- is one of five abstracts presented at AACR cancer and related biomedical sciences; cific Antigen, an Anti-Angiogenic Protein that have clinical implications for to encourage presentation and discussion Induces Apoptosis in Endothelial Cells / EntreMed’s leading drug candidates. / of new and important observations in the www.entremed.com www.entremed.com field; to foster public education, science education, and training; and to advance 8. IMMUNOMEDICS SCIENTISTS 10. DISCOVERY OF CANCER CELL the understanding of cancer etiology, pre- INVENT IMPROVED METHOD OF STRUCTURE OFFERS NEW TAR- vention, diagnosis, and treatment LABELING ANTIBODIES WITH RA- GETS FOR TREATMENT -- Scientists throughout the world. For more informa- DIOIODINE FOR CANCER have figured out the precise three-dimen- tion visit www.aacr.org

P. 8 US TOO! PCA HOTSHEET MAR / APR 2001 US TOO! INTERNATIONAL VISIT US ON THE INTERNET AT WWW.USTOO.ORG (PC SPES - continued from P.1) TABLE 3 TABLE 7 REMEMBER: This information is AGE OF RESPONDENTS provided for information only. Us Too! DOSAGE PER DAY Age Respondents % of Total does not endorse any treatment or Pills per Day Respondents distributor. For more information about 1 Pill 1 40-49 1 1% PC-SPES and/or alternate distributors 2 Pills 11 50-59 17 11% for this product contact: 3 Pills 20 60-69 48 34% 4 Pills 17 70-79 59 44% Botanic Lab (1-800-242-5555) 5 Pills 7 80-89 13 10% www.Botaniclab.com 6 Pills 42 137 Reporting 100% 7 Pills 6 or an alternate PC SPES website such 8 Pills 1 as: www.pc-spes.com 9 Pills 21 TABLE 8 10 Pills 1 QUALITY OF LIFE 12 Pills 7 (SCORING: 10 BEST, 1 WORST) 134 Reporting Level Respondents % of Total ALWAYS CONSULT WITH 10 24 19% TABLE 4 9 19 15% YOUR PERSONAL PHYSICIAN SIDE EFFECTS 8 33 26% BEFORE TAKING ANY (Some respondents reported 2 or more) 7 13 10% AND/OR Tender Breasts Most 6 9 7% Leg Cramps 31 5 24 19% DIETARY SUPPLEMENTS. Diarrhea 3 4 1 1% Low Libido Most 3 2 2% Nausea 3 2 1 1% Lost Appetite 2 1 0 0% Fatigue 3 126 Reporting 100% No Side Effects 23 71% are 7 and higher - feeling well 137 Reporting TABLE 5 TABLE 9 EMBOLISMS (BLOOD CLOTS) TREATMENTS BEFORE PC-SPES Location Respondents Treatments Respondents W.W. 35 Leg 9 (8 surface veins RP 19 (2 negative) - 1 deep vein) RT 14 (1 negative) ABOUT: Paul Anderson Foot 1 CHT 22 (1 negative) Paul is a prostate cancer survivor since Lung 1 (clot in one lung) Orch 4 - - - - - 1986. At that time Dr. Patrick Walsh at Brachy 3 Johns Hopkins removed his prostate and Of 11 embolisms, (6.5%) 5 were RT-CHT-Chemo 1 carried over from previous years. all was well for 9-1/2 years. Surprisingly, RT-CHT 6 (1 negative) my PSA started to rise, slowly at first - - - - - RT-Cryo-Brachy 1 There are no known fatalities and then faster. Then a miracle RT-CHT-Cryo 1 happened. Hank Porterfield, Us Too! when taking PC SPES RT-Chemo 1 (1 negative) - - - - - Chairman learned about PC SPES and RT-Brachy 1 (1 negative) initiated a study group of 12 prostate 10 of the 11 are continuing RP-RT 6 to take PC SPES after treatment cancer survivors, of which Paul was one. RP-CHT 2 Taking various numbers of pills, 10 out RP-RT-CHT 2 of 12 had dramatically positive results. TABLE 6 Orch-CHT 3 Three to four years later, all 10 SEX DRIVE Orch-RT-CHT 1 survivors have PSA readings at very low (SCORING: 10 BEST, 1 WORST) Orch-Brachy 1 levels - 9 are below 1.0. Paul’s PSA re- Rating Respondents % of Total Orch-RT 2 mains undetectable. 1 88 65.0% CHT-Chemo 3 2 23 17.0% 129 Reporting For over three years, Paul has given PC Legend 3 10 7.0% WW – Watchful Waiting SPES presentations to prostate cancer 4 4 3.0% RP – Radical Prostatectomy survivor groups on a volunteer basis. In 5 6 5.0% RT – Radiation Therapy the fall of 1999, Botaniclab executives 6 2 1.5% CHT – Combined Hormone Therapy thought it was a good idea for him to be- Orch – Orchyectomy (castration) 7 2 1.5% Brachy - Brachytherapy (seeds) come a distributor of PC SPES and some 8 1 1.0% Cryo – Cryosurgery (freeze) of their other herbal supplements. Paul 136 Reporting 100.0% Chemo – Chemotherapy graciously provides counseling, one on 10 taking Viagra Negative – PSA reduced then rose over time one, to those interested in PC-SPES. You can reach him at 1.888.784.0399.

US TOO! PCA HOTSHEET MAR / APR 2001 P. 9 PROSTATE CANCER PATIENT SUPPORT 1-800-80-US TOO! US TOO! INTERNATIONAL among African-American men in Central • SHAPPELL SB, Gupta RA, Manning S, QUARTERLY JOURNAL Harlem, New York City. Cancer 2001;91:164- Whitehead R, Boeglin WE, Schneider C et REVIEW - Q1 2001 172. al. 15S-Hydroxyeicosatetraenoic acid acti- The following prostate cancer related • CHENG L, Zincke H, Blute ML, Bergstralh vates peroxisome proliferator- activated re- EJ, Scherer B, Bostwick DG. Risk of prostate ceptor gamma and inhibits proliferation in articles have appeared in well-known carcinoma death in patients with lymph node PC3 prostate carcinoma cells. Cancer Res scientific journals. Abstracts only have metastasis. Cancer 2001;91:66-73. 2001; 61: 497-503. been posted at the US TOO! website • ITO K, Kubota Y, Yamamoto T, Suzuki K, • RASHID MG, Sanda MG, Vallorosi CJ, Rios- (www.ustoo.org). US TOO! cannot Fukabori Y, Kurokawa K et al. Long term fol- Doria J, Rubin MA, Day ML. Posttransla- provide copies of the complete article. low-up of mass screening for prostate carci- tional truncation and inactivation of human TO OBTAIN A COPY OF THE noma in men with initial prostate specific an- E-cadherin distinguishes prostate cancer from ARTICLE: take the citation to your tigen levels of 4.0 ng/ml or less. Cancer 2001; matched normal prostate. Cancer Res 2001; local public or hospital library. The 91: 744-751. 61: 489-92. librarian can assist you in obtaining a • VOLLMER RT. The correlation of serial pros- • HENSHALL SM, Quinn DI, Lee CS, Head copy of the article from their collection tate specific antigen measurements with clini- DR, Golovsky D, Brenner PC et al. Altered or from interlibrary loan. cal outcome after external beam radiation expression of androgen receptor in the ma- therapy of patients for prostate carcinoma. lignant epithelium and adjacent stroma is as- American Journal* o *f C*l i*nical Pathology Cancer 2001; 91: 1063-4. sociated with early relapse in prostate cancer. • ZHOU M, Patel A, Rubin MA. Prevalence and Cancer Genetics and Cytogenetics Cancer Res 2001; 61: 423-7. location of peripheral nerve found on prostate • OBA K, Matsuyama H, Yoshihiro S, Kishi F, • LI X, Marani M, Yu J, Nan B, Roth JA, Kagawa needle biopsy. Am J Clin Pathol 2001; 115: Takahashi M, Tsukamoto M et al. Two puta- S et al. Adenovirus-mediated Bax 39-43. tive tumor suppressor genes on chromosome overexpression for the induction of therapeu- • YAZIJI H, Davie PL, Gown AM. On the use arm 8p may play different roles in prostate can- tic apoptosis in prostate cancer. Cancer Res of cytokeratins 7 and 20 in the differentiation cer. Cancer Genet Cytogenet 2001; 124: 20- 2001; 61: 186-91. between transitional cell carcinoma and pros- 26. • DEGRADO TR, Coleman RE, Wang S, tate adenocarcinoma. Am J Clin Pathol 2001; • JORDAN JJ, Hanlon AL, Al-Saleem TI, Baldwin SW, Orr MD, Robertson CN et al. 115: 159-60. Greenberg RE, Tricoli JV. Loss of the short Synthesis and evaluation of 18F-labeled cho- American Journal of Human Genetics arm of the Y chromosome in human prostate line as an oncologic tracer for positron emis- • THOMPSON D, Easton D. Variation in can- carcinoma. Cancer Genet Cytogenet 2001; sion tomography: initial findings in PCa. Can- cer risks, by mutation position, in BRCA2 mu- 124: 122-126. cer Res 2001; 61: 110-7. tation carriers. Am J Hum Genet 2001; 68: • STREFFORD JC, Lillington DM, Young BD, • NELSON CP, Kidd LC, Sauvageot J, Isaacs 410-9. Oliver RT. The use of multicolor fluorescence WB, De Marzo AM, Groopman JD et al. Pro- • BOCK CH, Cunningham JM, McDonnell SK, technologies in the characterization of pros- tection against 2-hydroxyamino-1-methyl-6- Schaid DJ, Peterson BJ, Pavlic RJ et al. Analy- tate carcinoma cell lines. a comparison of mul- phenylimidazo[4,5- b]pyridine cytotoxicity sis of the Prostate Cancer-Susceptibility Lo- tiplex fluorescence in situ hybridization and and DNA adduct formation in human pros- cus HPC20 in 172 Families Affected by Pros- spectral karyotyping data. Cancer Genet tate by glutathione S-transferase P1. Cancer tate Cancer. Am J Hum Genet 2001; 68: 795- Cytogenet 2001; 124: 112-121. Res 2001; 61: 103-9. 801. Cancer Letter • PETER J, Unverzagt C, Krogh TN, Vorm O, • XU J, Zheng SL, Carpten JD, Nupponen NN, • DOK AN C, Yoshiki T, Lee G, Okada Y. Evalu- Hoesel W. Identification of precursor forms Robbins CM, Mestre J et al. Evaluation of ation of a rapid qualitative prostate specific of free prostate-specific antigen in serum of Linkage and Association of HPC2/ELAC2 in antigen assay, the One Step PSA(TM) test. prostate cancer patients by immunosorption Patients with Familial or Sporadic Prostate Cancer Lett 2001; 162: 135-9. and mass spectrometry. Cancer Res 2001; 61: 957-62. Cancer. Am J Hum Genet 2001; 68: 901-11. Cancer Research American Journal of Pathology • SAKKO AJ, Ricciardelli C, Mayne K, Tilley • SLAWIN KM, Shariat SF, Nguyen C, et al. WD, Lebaron RG, Horsfall DJ. Versican ac- • CAMPBELL CL, Jiang Z, Savarese DM, Detection of metastatic prostate cancer using Savarese TM. Increased Expression of the cumulation in human prostatic fibroblast cul- a splice variant-specific reverse transcriptase- tures is enhanced by prostate cancer cell-de- Interleukin-11 Receptor and Evidence of polymerase chain reaction assay for human STAT3 Activation in Prostate Carcinoma. Am rived transforming growth factor beta1. Can- glandular kallikrein. Cancer Res cer Res 2001; 61: 926-30. J Pathol 2001;158:25-32. 2000;60:7142-8. • HAO J, Jackson L, Calaluce R, McDaniel K, • WINTER RN, Kramer A, Borkowski A, • CORNFORD PA, Dodson AR, Parsons KF, et Kyprianou N. Loss of caspase-1 and caspase- Dalkin BL, Nagle RB. Investigation into the al. Heat shock protein expression indepen- Mechanism of the Loss of Laminin 5 3 protein expression in human PCa. Cancer dently predicts clinical outcome in prostate Res 2001; 61: 1227-32. (alpha3beta3gamma2) Expression in Prostate cancer. Cancer Res 2000;60:7099-105. Cancer. Am J Pathol 2001; 158: 1129-1135. • ROCCHI P, Boudouresque F, Zamora AJ, • WEN Y, Hu MC, Makino K, et al. HER-2/neu Muracciole X, Lechevallier E, Martin PM et American Journal of Surgical Pathology promotes androgen-independent survival and al. Expression of adrenomedullin and peptide • KRONZ JD, Shaikh AA, Epstein JI. Atypical growth of prostate cancer cells through the Akt amidation activity in human prostate cancer cribriform lesions on prostate biopsy. Am J pathway. Cancer Res 2000;60:6841-5. and in human prostate cancer cell lines. Can- Surg Pathol 2001; 25: 147-55. • NIMMANAPALLI R, Perkins CL, Orlando cer Res 2001; 61: 1196-206. British Journal of Cancer M, O’Bryan E, Nguyen D, Bhalla KN. Pre- • AFAR DE, Vivanco I, Hubert RS, Kuo J, Chen • TURNER SL, Gruenewald S, Spry N, Gebski treatment with paclitaxel enhances apo-2 E, Saffran DC et al. Catalytic cleavage of the V. Less pain does equal better quality of life ligand/tumor necrosis factor-related apoptosis- androgen-regulated TMPRSS2 protease re- following strontium-89 therapy for metastatic inducing ligand-induced apoptosis of PCa cells sults in its secretion by prostate and PCa epi- prostate cancer. Br J Cancer 2001; 84: 297- by inducing death receptors 4 and 5 protein thelia. Cancer Res 2001; 61: 1686-92. 302. levels. Cancer Res 2001; 61: 759-63. • SUZUKI S, Tadakuma T, Asano T, Hayakawa Cancer • YU DC, Chen Y, Dilley J, Li Y, Embry M, M. Coexpression of the partial androgen re- • ASHFORD AR, Albert SM, Hoke G, Cushman Zhang H et al. Antitumor synergy of CV787, ceptor enhances the efficacy of prostate-spe- LF, Miller DS, Bassett M. Prostate carcinoma a prostate cancer-specific adenovirus, and cific antigen promoter-driven suicide gene knowledge, attitudes, and screening behavior paclitaxel and docetaxel. Cancer Res 2001; therapy for PCa cells at low testosterone con- 61: 517-25. centrations. Cancer Res 2001; 61: 1276-9. P. 10 US TOO! PCA HOTSHEET MAR / APR 2001 US TOO! INTERNATIONAL VISIT US ON THE INTERNET AT WWW.USTOO.ORG • BORRELLI MJ, Schoenherr DM, Wong A, cer in Germany: A Study Using Digital Rectal conformal radiation therapy: Comparing late Bernock LJ, Corry PM. Heat-activated Examination and 4.0 ng/ml Prostate-Specific bowel and bladder quality of life symptoms transgene expression from adenovirus vec- Antigen as Cutoff. Eur Urol 2001; 39: 131- to that of the normal population. Int J Radiat tors infected into human prostate cancer cells. 137. Oncol Biol Phys 2001; 49: 51-59. Cancer Res 2001; 61: 1113-21. • HEIDENREICH A, von Knobloch R, • TEH BS, Mai W, Uhl BM, Augspurger ME, Cancer Treat Res Hofmann R. Current Status of Cytotoxic Che- Grant WH, Lu HH et al. Intensity-modulated • NABHAN C, Bergan R. Chemoprevention in motherapy in Hormone Refractory Prostate radiation therapy (IMRT) for prostate cancer prostate cancer. Cancer Treat Res 2001; 106: Cancer. Eur Urol 2001; 39: 121-130. with the use of a rectal balloon for prostate 103-36. Genes Chromosomes Cancer immobilization: acute toxicity and dose-vol- • GRONBERG H, Ahman AK, Emanuelsson ume analysis. Int J Radiat Oncol Biol Phys Clinical Cancer Research M, Bergh A, Damber JE, Borg A A. BRCA2 2001; 49: 705-712. • COOPER CR, McLean L, Walsh M, et al. Pref- mutation in a family w/ hereditary PCa. Genes • BEN-JOSEF E, Porter AT, Han S, Mertens W, erential adhesion of prostate cancer cells to Chromosomes Cancer 2001; 30: 299-301. Chuba P, Fontana J et al. Neoadjuvant bone is mediated by binding to bone marrow • PADALECKI SS, Johnson-Pais TL, Killary estramustine and followed by con- endothelial cells as compared to extracellular AM, Leach RJ. Chromosome 18 suppresses current estramustine and definitive radio- matrix components in vitro. Clin Cancer Res the tumorigenicity of PCa cells. Genes Chro- therapy for locally advanced prostate cancer: 2000;6:4839-47. mosomes Cancer 2001; 30: 221-229. Feasibility and preliminary results. Int J Radiat • SCHLEUTKER J, Matikainen M, Smith J, et • AURICH-COSTA J, Vannier A, Gregoire E, Oncol Biol Phys 2001; 49: 699-703. al. A genetic epidemiological study of heredi- Nowak F, Cherif D. IPM-FISH, a new M- • JACKSON A, Skwarchuk MW, Zelefsky MJ, tary prostate cancer (HPC) in Finland: frequent FISH approach using IRS-PCR painting Cowen DM, Venkatraman ES, Levegrun S et HPCX linkage in families with late-onset dis- probes: application to the analysis of seven al. Late rectal bleeding after conformal radio- ease. Clin Cancer Res 2000;6:4810-5. human prostate cell lines. Genes Chromo- therapy of prostate cancer (II): volume effects • WASHBURN JG, Wojno KJ, Dey J, Powell and dose-volume histograms. Int J Radiat IJ, Macoska JA. 8pter-p23 deletion is associ- somes Cancer 2001; 30: 143-60. International Journal of Cancer Oncol Biol Phys 2001; 49: 685-698. ated with racial differences in prostate cancer • D’AMICO AV, Schultz D, Silver B, Henry L, outcome. Clin Cancer Res 2000;6:4647-52. • CHIEN J, Shah GV. Role of stimulatory gua- nine nucleotide binding protein (GSalpha) in Hurwitz M, Kaplan I et al. The clinical utility • MEHTA R, Kyshtoobayeva A, Kurosaki T, of the percent of positive prostate biopsies in Small EJ, Kim H, Stroup R et al. Independent proliferation of PC-3M prostate cancer cells. Int J Cancer 2001;91:46-54. predicting biochemical outcome following ex- association of angiogenesis index with out- ternal-beam radiation therapy for patients with come in prostate cancer. Clin Cancer Res 2001; • CHEN Y, Hughes-Fulford M. Human pros- tate cancer cells lack feedback regulation of clinically localized prostate cancer. Int J Radiat 7: 81-8. Oncol Biol Phys 2001; 49: 679-684. • HILLMAN GG, Forman JD, Kucuk O, low-density lipoprotein receptor and its regu- lator, SREBP2. Int J Cancer 2001;91:41-5. • FENWICK JD, Khoo VS, Nahum AE, Yudelev M, Maughan RL, Rubio J et al. Sanchez-Nieto B, Dearnaley DP. Correlations Genistein potentiates the radiation effect on • SCHUMACHER G, Bruckheimer EM, Beham AW, et al. Molecular determinants of between dose-surface histograms and the in- prostate carcinoma cells. Clin Cancer Res cidence of long- term rectal bleeding follow- 2001; 7: 382-90. cell death induction following adenovirus- mediated gene transfer of wild-type p53 in PCa ing conformal or conventional radiotherapy Endocrinology cells. Int J Cancer 2001;91:159-166. treatment of prostate cancer. Int J Radiat Oncol • DAMON SE, Plymate SR, Carroll JM, et al. • BERGSTROM A, Pisani P, Tenet V, Wolk A, Biol Phys 2001; 49: 473-480. Transcriptional Regulation of Insulin-Like Adami HO. Overweight as an avoidable cause • TEH BS, Mai W, Augspurger ME, Uhl BM, Growth Factor-I Receptor Gene Expression of cancer in Europe. Int J Cancer 2001; 91: McGary J, Dong L et al. Intensity modulated in Prostate Cancer Cells. Endocrinology 421-30. radiation therapy (IMRT) following prostate- 2001;142:21-27. • FERNANDEZ PL, Farre X, Nadal A, ctomy: more favorable acute genitourinary European Urology Fernandez E, Peiro N, Sloane BF et al. Ex- toxicity profile compared to primary IMRT • ABRAHAMSSON PA. Treatment of locally pression of cathepsins B and S in the progres- for prostate cancer. Int J Radiat Oncol Biol advanced prostate cancer - A new role for sion of prostate carcinoma. Int J Cancer 2001; Phys 2001; 49: 465-472. antiandrogen monotherapy? Eur Urol 2001; 95: 51-5. • DAMEN EM, Brugmans MJ, van der Horst A, Bos L, Lebesque JV, Mijnheer BJ et al. 39 Suppl 1: 22-8. 3. International Journal of Oncology • NEWLING D. Advanced prostate cancer: im- Planning, computer optimization, and dosim- mediate or deferred hormone therapy? Eur • DAVIES G, Jiang WG, Mason MD. The in- etric verification of a segmented irradiation Urol 2001; 39 Suppl 1: 15-21. teraction between beta-catenin, GSK3beta and technique for prostate cancer. Int J Radiat • LEIN M, Jung K, Elgeti U, Petras T, Stephan APC after motogen induced cell-cell disso- Oncol Biol Phys 2001; 49: 1183-1195. C, Brux B et al. Comparison of the Clinical ciation, and their involvement in signal trans- • HODGSON DC, Catton CN, Warde P, Validity of Free Prostate-Specific Antigen, Al- duction pathways in prostate cancer. Int J Gospodarowicz MK, Milosevic MF, McLean pha-1 Antichymotrypsin-Bound Prostate-Spe- Oncol 2001; 18: 843-847. M B M et al. The impact of irregularly rising cific Antigen and Complexed Prostate-Spe- Int’l J of Radiation Oncol Biology Physics prostate-specific antigen and “impending fail- cific Antigen in Prostate Cancer Diagnosis. Eur • CELLA L, Lomax A, Miralbell R. Potential ure” on the apparent outcome of localized pros- Urol 2001; 39: 57-64. role of intensity modulated proton beams in tate cancer following radiotherapy. Int J Radiat • CALDIROLI M, Cova V, Lovisolo JA, Reali prostate cancer radiotherapy. Int J Radiat Oncol Oncol Biol Phys 2001; 49: 957-963. L, Bono AV. Antiandrogen Withdrawal in the Biol Phys 2001; 49: 217-223. • HORWITZ EM, Winter K, Hanks GE, Lawton Treatment of Hormone-Relapsed Prostate • MARTINEZ AA, Pataki I, Edmundson G, CA, Russell AH, Machtay M. Subset analysis Cancer: Single Institutional Experience. Eur Sebastian E, Brabbins D, Gustafson G. Phase of RTOG 85-31 and 86-10 indicates an ad- Urol 2001; 39 Suppl S2: 6-10. II prospective study of the use of conformal vantage for long- term vs. short-term adjuvant • AALTOMAA S, Lipponen P, Ala-Opas M, high-dose-rate brachytherapy as monotherapy hormones for patients with locally advanced Kosma VM. Expression and Prognostic Value for the treatment of favorable stage prostate nonmetastatic prostate cancer treated with ra- of CD44 Standard and Variant v3 and v6 cancer: A feasibility report. Int J Radiat Oncol diation therapy. Int J Radiat Oncol Biol Phys Isoforms in Prostate Cancer. Eur Urol 2001; Biol Phys 2001; 49: 61-69. 2001; 49: 947-956. 39: 138-144. • HANLON AL, Watkins Bruner D, Peter R, • SANCHEZ-NIETO B, Nahum AE, Dearnaley • LUBOLDT HJ, Bex A, Swoboda A, Husing J, Hanks GE. Quality of life study in prostate DP. Individualization of dose prescription Rubben H. Early Detection of Prostate Can- cancer patients treated with three- dimensional based on normal-tissue dose- volume and ra-

US TOO! PCA HOTSHEET MAR / APR 2001 P. 11 PROSTATE CANCER PATIENT SUPPORT 1-800-80-US TOO! US TOO! INTERNATIONAL diosensitivity data. Int J Radiat Oncol Biol • NEWSCHAFFER CJ, Otani K, Penberthy L. regulated by androgens in hormone respon- Phys 2001; 49: 487-99. RESPONSE: Re: Causes of Death in Elderly sive human prostate carcinoma: evidence for • BRAHME A. Individualizing cancer treatment: Prostate Cancer Patients and in a Comparison androgen dependent destabilization of vascu- biological optimization models in treatment Nonprostate Cancer Cohort. J Natl Cancer Inst lar endothelial growth factor transcripts. J Urol planning and delivery. Int J Radiat Oncol Biol 2001; 93: 398. 2001; 165: 688-693. Phys 2001; 49: 327-37. • ROMANO PS. Re: Causes of Death in Eld- • SNEEUW KC, Albertsen PC, Aaronson NK. International Journal of Urology erly Prostate Cancer Patients and in a Com- Comparison of patient and spouse assessments • MATSUYAMA H, Baba Y, Yamakawa G, parison Nonprostate Cancer Cohort. J Natl of health related wuality of life in men with Yamamoto N, Naito K. Diagnostic value of Cancer Inst 2001; 93: 397-398. metastatic prostate cancer. J Urol 2001; 165: prostate-specific antigen-related parameters in • HOFFMAN RM, Gilliland FD, Eley JW, 478-482. discriminating prostate cancer. Int J Urol Harlan LC, Stephenson RA, Stanford JL et al. • NARAIN V, Tiguert R, Banerjee M, Grignon 2000;7:409-14. Racial and Ethnic Differences in Advanced- D, Wood DP, Powell IJ. Biochemical recur- • HAYAKAWA K, Matsumoto M, Aoyagi T, Stage Prostate Cancer: the Prostate Cancer rence after radical prostatectomy in black and Miyaji K, Hata M. Prostate cancer with mul- Outcomes Study. J Natl Cancer Inst 2001; 93: white american men with a positive or nega- tiple lung metastases in a hemodialysis patient. 388-395. tive family history of prostate cancer. J Urol Int J Urol 2000; 7: 464-466. • BENOWITZ S. New Gene Finding May Yield 2001; 165: 474-477. • NAGAKAWA O, Ogasawara M, Murata J, Clues to Prostate Cancer Complexity. J Natl • FAAS FH, Dang AQ, White J, Schaefer R, Fuse H, Saiki I. Effect of prostatic neuropep- Cancer Inst 2001; 93: 344-345. Johnson D. Increased prostatic tides on migration of prostate cancer cell lines. • JONES J. African-Americans And Prostate lysophosphatidlcholine acyl transferase activ- Int J Urol 2001; 8: 65-70. Cancer: Why the Discrepancies? J Natl Can- ity in human prostate cancer: a marker for • KITAMURA T. Necessity of re-evaluation of cer Inst 2001; 93: 342-344. malignancy. J Urol 2001; 165: 463-468. sodium (EMP) as a Journal of Nuclear Medicine • GOLDSTEIN IS. Editorial: Erectile function treatment option for first-line monotherapy in • IYER RV, Haynes PT, Schneider RF, Movsas after treatment for prostate cancer. J Urol 2001; advanced PCa. Int J Urol 2001; 8: 33-36. B, Chapman JD. Marking hypoxia in rat pros- 165: 440. Journal of the American Medical Association tate carcinomas with beta-D-[125I]azomycin • STOCK RG, Kao J, Stone NN. Penile erectile • VICINI FA, Kestin L, Martinez A. Biochemi- galactopyranoside and. J Nucl Med 2001; 42: function after permanenet radioactive seed cal outcomes of treatment for prostate cancer. 337-44. implantation for treatment of prostate cancer. JAMA 2000;284:2869. Journal of Urology J Urol 2001; 165: 436-439. • SIEGEL T, Moul JW, Spevak M, Alvord WG, Journal of Clinical Oncology • GOHJI K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M. Expression of endothelin re- Costabile RA. The development of erectile • SMALL EJ, McMillan A, Meyer M, Chen L, dysfunction in men treated for prostate can- Slichenmyer WJ, Lenehan PF et al. Serum ceptor A associated with prostate cancer pro- gression. J Urol 2001; 165: 1033-1036. cer. J Urol 2001; 165: 430-435. Prostate-Specific Antigen Decline as a Marker • WALSH PC. Modern prostate brachytherapy: of Clinical Outcome in Hormone-Refractory • LITWIN MS, Lubeck DP, Stoddard ML, Pasta DJ, Flanders SC, Henning JM. Quality of life prostate specific antigen results in 219 patients PCa Patients: Association With Progression- with up to 12 years of observed follow-up. J Free Survival, Pain End Points, and Survival. before death for men with prostate cancer: re- sults from the CaPSURE datebase. J Urol Urol 2001; 165: 318-9. J Clin Oncol 2001; 19: 1304-1311. • MOUDOUNI SM, En-Nia I, Rioux-Leclerq • MADALINSKA JB, Essink-Bot ML, de 2001; 165: 871-875. • IZAWA JI, Perrotte P, Greene GF, Scott S, Levy N, Manunta A, Guille F, Lobel B. Prostatic Koning HJ, Kirkels WJ, van Der Maas PJ, metastases of renal cell carcinoma. J Urol Schroder FH. Health-Related Quality-of-Life L, McGuire E et al. Local tumor control with salvage cryotherpay for locally recurrent pros- 2001; 165: 190-1. Effects of Radical Prostatectomy and Primary • RUBIN MA, Mucci NR, Manley S, Sanda M, Radiotherapy for Screen-Detected or Clini- tate cancer after external beam radiotherapy. J Urol 2001; 165: 867-870. Cushenberry E, Strawderman M et al. Predic- cally Diagnosed Localized Prostate Cancer. J tors of Gleason pattern 4/5 prostate cancer on Clin Oncol 2001; 19: 1619-28. • HAN M, Pound CR, Potter SR, Partin AW, Epstein JI, Walsh PC. Isolated local recurrence prostatectomy specimens: can high grade tu- • GANZ PA, Litwin MS. Prostate cancer: the mor be predicted preoperatively? J Urol 2001; price of early detection. J Clin Oncol 2001; is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgi- 165: 114-8. 19: 1587-8. • JOHN H, Hauri D, Leuener M, Reinecke M, Journal of the National Cancer Institute cal margins: therapeutic implications. J Urol 2001; 165: 864-866. Maake C. Evidence of trigonal denervation • THOMPSON IM, Tangen CM, Tolcher A, and reinnervation after radical retropubic pros- Crawford ED, Eisenberger M, Moinpour CM. • GRAEFEN M, Haese A, Pichlmeier U, Ham- merer PG, Noldus J, Butz K et al. A validated tatectomy. J Urol 2001; 165: 111-3. Association of African-American Ethnic • HOLZBEIERLEIN J, Peterson M, Smith JA Background With Survival in Men With Meta- strategy for side specific prediction of organ confined prostate cancer: a tool to select for JR. Variability of results of cavernous nerve static Prostate Cancer. J Natl Cancer Inst 2001; stimulation during radical prostatectomy. J 93: 219-225. nerve sparing radical prostatectomy. J Urol 2001; 165: 857-863. Urol 2001; 165: 108-10. • FERNANDEZ A, Udagawa T, Schwesinger • NAUGHTON CK, Miller DC, Yan Y. Impact C, Beecken WD, Achilles-Gerte E, • GILLILAND FD, Gleason DF, Hunt WC, Stone N, Harlan LC, Key CR. Trends in of transrectal ultrasound guided prostate bi- McDonnell TJ et al. Angiogenic Potential of opsy on quality of life: a prospective random- Prostate Carcinoma Cells Overexpressing bcl- Gleason score for prostate cancer diagnosed between 1983 and 1993 J Urol 2001; 165: 846- ized trial comparing 6 versus 12 cores. J Urol 2. J Natl Cancer Inst 2001; 93: 208-213. 2001; 165: 100-3. • DALKIN BL. Re: Health Outcomes After 850. • BABAIAN RJ, Johnston DA, Naccarato W, • COFFEY RN, Watson RW, Fitzpatrick JM. Prostatectomy or Radiotherapy for Prostate Signaling for the caspases: their role in pros- Cancer: Results From the PCa Outcomes Ayala A, Bhadkamkar VA, Fritsche HA JR. The incidence of prostate cancer in a screen- tate cell apoptosis. J Urol 2001; 165: 5-14. Study. J Natl Cancer Inst 2001; 93: 401. • ALBERTSEN PC, Albertsen PC. Compari- • POTOSKY AL, Legler J, Hoffman RM, ing population with a serum prostate specific antigen between 2.5 and 4.0 Ng/ml: relation son of recommendations by urologists and ra- Gilliland FD. RESPONSE: Re: Health Out- diation oncologists for treatment of clinically comes After Prostatectomy or Radiotherapy to biopsy strategy. J Urol 2001; 165: 757-760. • STEWART RJ, Panigrahy D, Flynn E, localized prostate cancer. J Urol 2001; 165: for Prostate Cancer: Results From the Pros- 731-2. tate Cancer Outcomes Study. J Natl Cancer Folkman J. Vascular endothelial growth fac- tor expression and tumor angiogenesis are • DASARI VK, Goharderakhshan RZ, Inst 2001; 93: 401-402. Perinchery G, Li LC, Tanaka Y, Alonzo J et al.

P. 12 US TOO! PCA HOTSHEET MAR / APR 2001 US TOO! INTERNATIONAL VISIT US ON THE INTERNET AT WWW.USTOO.ORG Expression analysis of y chromosome genes mean nuclear volume predicts tumor biology • PIENTA KJ, Fisher EI, Eisenberger MA, Mills in human prostate cancer. J Urol 2001; 165: of clinically organ-confined prostate cancer. GM, Goodwin JW, Jones JA et al. A phase II 1335-41. Prostate 2001; 46: 134-141. trial of estramustine and etoposide in hormone • NAUGHTON M, Picus J, Zhu X, Catalona • LILLEBY W, Paus E, Skovlund E, Fossa SD. refractory prostate cancer: A Southwest On- WJ, Vollmer RT, Humphrey PA. Scatter fac- Prognostic value of neuroendocrine serum cology Group trial (SWOG 9407). Prostate tor-hepattocyte growth factor elevation in the markers and PSA in irradiated patients with 2001; 46: 257-261. serum of patients with prostate cancer. J Urol pN0 localized prostate cancer. Prostate 2001; • TALWAR GP, Gupta R, Gupta SK, Malhotra 2001; 165: 1325-1328. 46: 126-133. R, Khanna R, Mitra DK et al. A monoclonal • BOYLE BJ, Zhao XY, Cohen P, Feldman D. • LEUSCHNER C, Enright FM, Melrose PA, antibody cytolytic to androgen independent Insulin-like growth factor binding protein-3 Hansel W. Targeted destruction of androgen- DU145 and PC3 human prostatic carcinoma mediates 1alpha,25- dihydroxyvitamin d3 sensitive and -insensitive prostate cancer cells cells. Prostate 2001; 46: 207-13. growth inhibition in the lncap prostate cancer and xenografts through luteinizing hormone • BELLO-DEOCAMPO D, Kleinman HK, cell line through p21/waf1. J Urol 2001; 165: receptors. Prostate 2001; 46: 116-125. Deocampo ND, Webber MM. Laminin-1 and 1319-24. • BHATIA N, Agarwal R. Detrimental effect of alpha6beta1 integrin regulate acinar morpho- • HORWITZ EM, Pinover And WH, Hanks GE, cancer preventive phytochemicals silymarin, genesis of normal and malignant human pros- Critz FA, Williams WH, Levinson AK et al. genistein and epigallocatechin 3-gallate on epi- tate epithelial cells. Prostate 2001; 46: 142-53. Re: simultaneous irradiation for prostate can- genetic events in human prostate carcinoma Semin Oncol cer: intermediate results with modern tech- DU145 cells. Prostate 2001; 46: 98-107. • CHAY C, Smith DC. Adjuvant and niques. J Urol 2001; 165: 1224. • MADALINSKA JB, Essink-Bot ML, de neoadjuvant therapy in prostate cancer. Semin New England Journal of Medicine Koning HJ, Kirkels WJ, van Der Maas PJ, Oncol 2001; 28: 3-12. • D’AMICO AV, Cormack RA, Tempany CM. Schroder FH. Health-related quality of life in Urol Int MRI-guided diagnosis and treatment of pros- patients with screen-detected versus clinically • DRINIS S, Finkelstein MP, Tortorelis DG, tate cancer. N Engl J Med 2001; 344: 776-7. diagnosed prostate cancer preceding primary Konno S, Choudhury MS. Five-Year Prog- Oncology treatment. Prostate 2001; 46: 87-97. nosis after Radical Prostatectomy in a Patient • NISHIMURA K, Nonomura N, Ono Y, et al. • AALAMIAN M, Pirtskhalaishvili G, Nunez with Localized Prostate Cancer and Inciden- Oral Combination of , A, Esche C, Shurin GV, Huland E et al. Hu- tal Non-Hodgkin’s Lymphoma. Urol Int 2001; Uracil plus and Estramustine for Hor- man prostate cancer regulates generation and 66: 105-107. maturation of monocyte- derived dendritic mone-Refractory Prostate Cancer. Oncology Urology 2001;60:49-54. cells. Prostate 2001; 46: 68-75. • CHANG S, Hursting SD, Contois JH, Strom • NAM RK, Toi A, Vesprini D, Ho M, Chu W, Proceedings of the Natl Aca of Sci U S A SS, Yamamura Y, Babaian RJ et al. Leptin and Harvie S et al. V89L polymorphism of type- • SAFFRAN DC, Raitano AB, Hubert RS, Witte prostate cancer. Prostate 2001; 46: 62-67. 2, 5-alpha reductase enzyme gene predicts ON, Reiter RE, Jakobovits A. Anti-PSCA • XI SC, Siu SW, Fong SW, Shiu SY. Inhibition prostate cancer presence and progression. mAbs inhibit tumor growth and metastasis for- of androgen-sensitive LNCaP prostate cancer Urology 2001; 57: 199-204. mation and prolong the survival of mice bear- growth in vivo by melatonin: Association of • SAMADI AA, Fullerton SA, Tortorelis DG, ing human prostate cancer xenografts. Proc antiproliferative action of the pineal hormone Johnson GB, Davidson SD, Choudhury MS Natl Acad Sci U S A 2001; 98: 2658-2663. with mt(1) receptor protein expression. Pros- et al. Glyoxalase I phenotype as a potential • KANG HY, Lin HK, Hu YC, Yeh S, Huang tate 2001; 46: 52-61. risk factor for prostate carcinoma. Urology KE, Chang C. From transforming growth fac- • ANIDJAR M, Villette JM, Devauchelle P, Delisle 2001; 57: 183-187. tor-beta signaling to androgen action: Identi- F, Cotard JP, Billotey C et al. In vivo model mim- • KIRATLI BJ, Srinivas S, Perkash I, Terris MK. fication of Smad3 as an androgen receptor icking natural history of dog prostate cancer us- Progressive decrease in bone density over 10 coregulator in prostate cancer cells. Proc Natl ing DPC-1, a new canine prostate carcinoma years of androgen deprivation therapy in pa- Acad Sci U S A 2001; 98: 3018-3023. cell line. Prostate 2001; 46: 2-10 tients with prostate cancer. Urology 2001; 57: Prostate • KWABI-ADDO B, Ropiquet F, Giri D, Ittmann 127-132. • CUI J, Rohr LR, Swanson G, Speights VO, M. Alternative splicing of fibroblast growth • OH WK, George DJ, Hackmann K, Manola J, Maxwell T, Brothma AR. Hypermethylation factor receptors in human prostate cancer. Pros- Kantoff PW. Activity of the herbal combina- of the caveolin-1 gene promoter in prostate tate 2001; 46: 163-172. tion, PC-SPES, in the treatment of patients with cancer. Prostate 2001; 46: 249-256. • MORETTI RM, Marelli MM, Motta M, androgen-independent prostate cancer. Urol- • DAVIS TL, Cress AE, Dalkin BL, Nagle RB. Polizzi D, Monestiroli S, Pratesi G et al. Acti- ogy 2001; 57: 122-126. Unique expression pattern of the alpha6beta4 vation of the orphan nuclear receptor • BONO AV, Pagano F, Montironi R, Zattoni F, integrin and laminin-5 in human prostate car- RORalpha induces growth arrest in androgen- Manganelli A, Selvaggi FP et al. Effect of com- cinoma. Prostate 2001; 46: 240-248. independent DU 145 prostate cancer cells. plete androgen blockade on pathologic stage • ROKMAN A, Koivisto PA, Matikainen MP, Prostate 2001; 46: 327-335. and resection margin status of prostate can- Kuukasjarvi T, Poutiainen M, Helin HJ et al. • HARADA S, Keller ET, Fujimoto N, Koshida cer: progress pathology report of the Italian Genetic changes in familial prostate cancer by K, Namiki M, Matsumoto T et al. Long-term PROSIT study. Urology 2001; 57: 117-121. comparative genomic hybridization. Prostate exposure of tumor necrosis factor alpha causes • KATZ G, Rodriguez R. Use of a modified 2001; 46: 233-239. hypersensitivity to androgen and anti-andro- American Urological Association Symptom • EL GEDAILY A, Bubendorf L, Willi N, Fu gen withdrawal phenomenon in LNCaP pros- Score for the evaluation of the quality of life W, Richter J, Moch H et al. Discovery of new tate cancer cells. Prostate 2001; 46: 319-326. of patients with prostate cancer. Urology 2001; DNA amplification loci in prostate cancer by • ENGEDAL N, Saatcioglu F. Ceramide-in- 57: 112-116. comparative genomic hybridization. Prostate duced cell death in the prostate cancer cell line • LIU IJ, Zafar MB, Lai Y, Segall GM, Terris 2001; 46: 184-190. LNCaP has both necrotic and apoptotic fea- MK. Fluorodeoxyglucose positron emission • VIS AN, Hoedemaeker RF, van Der Kwast tures. Prostate 2001; 46: 289-297. tomography studies in diagnosis and staging TH, Schroder FH. Defining the window of • LANIADO ME, Fraser SP, Djamgoz MB. of clinically organ-confined prostate cancer. opportunity in screening for prostate cancer: Voltage-gated K(+) channel activity in human Urology 2001; 57: 108-111. Validation of a predictive tumor classification prostate cancer cell lines of markedly differ- • SHU HG, Lee TT, Vigneauly E, Xia P, Pickett model. Prostate 2001; 46: 154-162. ent metastatic potential: Distinguishing char- B, Phillips TL et al. Toxicity following high- • ARAI Y, Okubo K, Terada N, Matsuta Y, acteristics of PC-3 and LNCaP cells. Prostate dose three-dimensional conformal and inten- Egawa S, Kuwao S et al. Volume-weighted 2001; 46: 262-274. sity- modulated radiation therapy for clinically

US TOO! PCA HOTSHEET MAR / APR 2001 P. 13 PROSTATE CANCER PATIENT SUPPORT 1-800-80-US TOO! US TOO! INTERNATIONAL localized prostate cancer. Urology 2001; 57: • TONGCO WP, Wehner MS, Basler JW. Does Vince was a prostate cancer survivor and 102-107. urethral-sparing prostatectomy risk residual a founding member and member of the • VERHAGE BA, Baffoe-Bonnie AB, Baglietto prostate cancer? Urology 2001; 57: 495-8. Board of Directors of Us Too! Interna- L, Smith DS, Bailey-Wilson JE, Beaty TH et • BATUELLO JT, Gamito EJ, Crawford ED, tional. al. Autosomal dominant inheritance of pros- Han M, Partin AW, McLeod DG et al. Artifi- tate cancer: a confirmatory study. Urology cial neural network model for the assessment Always generous, Vince was a member 2001; 57: 97-101. of lymph node spread in patients with clini- of the Hyde Park, IL Kiwanis chapter, • SCHRODER FH, Roobol-Bouts M, Vis AN, cally localized prostate cancer. Urology 2001; served as president of the South Side van der Kwast T, Kranse R. Prostate-specific 57: 481-5. antigen-based early detection of prostate can- • YU H, Nicar MR, Shi R, Berkel HJ, Nam R, Swedish Club in 1957, was a trustee of cer- validation of screening without rectal ex- Trachtenberg J et al. Levels of insulin-like the Cancer Foundation at the University amination. Urology 2001; 57: 83-90. growth factor I (IGF-I) and IGF binding pro- of Chicago, a board member of the Cov- • SHALEV M, Thompson TC, Kadmon D, teins 2 and 3 in serial postoperative serum enant Benevolence Community’s Ayala G, Kernen K, Miles BJ. Gene therapy samples and risk of prostate cancer recurrence. Bjorklund House, an enabling residence for prostate cancer. Urology 2001; 57: 8-16. Urology 2001; 57: 471-5. for disabled adults, and was recently • MUENCHEN HJ, Poncza PJ, Pienta KJ. Dif- • LANGE PH. PROSTASCINT scan for stag- named an honorary vice president of the ferent docetaxel-induced apoptotic pathways ing prostate cancer. Urology 2001; 57: 402-6. Indiana Society of Chicago. are present in prostate cancer cell lines LNCaP and PC-3. Urology 2001; 57: 366-370. • EGEVAD L. Reproducibility of Gleason grad- * * * * * * * * * * * * * * * * ing of prostate cancer can be improved by the use of reference images. Urology 2001; 57: VINCE YOUNG 291-295. (continued from Page 1) • CHEUNG R, Altschuler MD, D’Amico AV, Malkowicz SB, Wein AJ, Whittington R. ROC optimization may improve risk stratification Mr. Young put in during that time appar- of prostate cancer patients. Urology 2001; 57: ently set the pace for him throughout his 286-290. life, said Mr. Young’s son, James. Mr. • CLARK PE, Peereboom DM, Dreicer R, Levin Young retired in 1995, handing the busi- HS, Clark SB, Klein EA. Phase II trial of ness over to son, Richard, who died two neoadjuvant estramustine and etoposide plus months ago. radical prostatectomy for locally advanced prostate cancer. Urology 2001; 57: 281-285. “No matter what it was, he was able to • KNIGHT SJ, Chmiel JS, Sharp LK, Kuzel T, complete a project. It was very high qual- Nadler RB, Fine R et al. Spouse ratings of qual- ity,” said Ron O’Drobinak, project man- ity of life in patients with metastatic prostate ager at the U. of C. Hospitals, who added cancer of lower socioeconomic status: an as- “Mr. Young definitely had his heart and VINCE YOUNG sessment of feasibility, reliability, and valid- soul into it.” ity. Urology 2001; 57: 275-280. tickles the ivories for an • PAUTLER SE, Tan JK, Dugas GR, Pus N, Mr. Young paid extraordinary attention appreciative audience Ferri M, Hardie WR et al. Use of the internet to details while on job sites, and expected for self-education by patients with prostate can- the same drive from employees. Along cer. Urology 2001; 57: 230-233. the way, his work in specialized construc- Throughout his life he was active in • CARROLL P, Coley C, McLeod D, tion became much sought after by Insti- church, both at Trinity Covenant Church Schellhammer P, Sweat G, Wasson J et al. tutions and culminated in his relationship in Oak Lawn, IL and in Bethany Beach, Prostate-specific antigen best practice policy- Michigan. part II: prostate cancer staging and post-treat- with U. of C. Hospitals. ment follow-up. Urology 2001; 57: 225-229. The son of Swedish Immigrants, he grew • CARROLL P, Coley C, McLeod D, Off the job Vince was a man who enjoyed light moments. He was also as outgoing up in the South Shore neighborhood and Schellhammer P, Sweat G, Wasson J et al. was a 1934 graduate of Calumet High Prostate-specific antigen best practice policy- as a showman, an amateur pianist almost part I: early detection and diagnosis of pros- as widely known for his ability to tickle School, where he met Leona Jane Birney; tate cancer. Urology 2001; 57: 217-224. the ivories as for his proficiency in erect- she became his sweetheart and they were • MOGHADDAMI M, Cohen P, Stapleton AM, ing buildings. His lifelong interest in married in 1938. Brown MP. CD40 is not detected on human music led him to play the piano for many prostate cancer cells by immunohistologic social and church groups. In addition to his wife and son James, Mr. techniques. Urology 2001; 57: 573-8. Young is survived by two daughters, • LAI S, Lai H, Lamm S, Obek C, Krongrad A, For years he played the piano at weekly Patricia Johnson and Barbara Styles; an- Roos B. Radiation therapy in non-surgically- Kiwanis club meetings and, at the other son, Eric; four grandchildren; and treated nonmetastatic prostate cancer: geo- Mitchell Hospital at the University of five great-grandchildren. His son Rich- graphic and demographic variation. Urology Chicago, where, after finishing the grand ard preceded Vince in death October 11, 2001; 57: 510-7. marble entrance and lobby in the mid- 2000. • PENSON DF, Schonfeld WH, Flanders SC, 1980’s, he donated a piano, and then Henke CJ, Warolin KL, Carroll PR et al. Re- came to the lobby every Tuesday until He will continue to be remembered by lationship of first-year costs of treating local- 1996 to play it for an hour for the enjoy- family and friends as truly being - ized PCa to initial choice of therapy and stage Young at Heart. at diagnosis: results from the CAPSURE da- ment of patients, and staff. tabase. Urology 2001; 57: 499-503.

P. 14 US TOO! PCA HOTSHEET MAR / APR 2001 US TOO! INTERNATIONAL VISIT US ON THE INTERNET AT WWW.USTOO.ORG

(CLINICAL TRIALS - Continued from Page 3) (PSA) Vaccine and Recombinant Vaccinia 55. Phase II Study of Flutamide and PSA Vaccine in Patients With Advanced Finasteride in Patients with Elevated Se- 24. Phase I/II Study of Active Immunotherapy Adenocarcinoma of the Prostate rum PSA After Radiation Therapy or Radi- With Prostate Specific Antigen RNA 39. Phase II Randomized Study of SU5416 cal Prostatectomy for Adenocarcinoma of Pulsed Autologous Dendritic Cells in Pa- Versus Dexamethasone in Patients With the Prostate tients With Metastatic Prostate Cancer Hormone Refractory Prostate Cancer 56. Phase II Study of Green Tea Extract in 25. Phase I/II Study of Estramustine, 40. Phase II Randomized Study of Vaccine Patients With Androgen Independent Vinorelbine, and Paclitaxel in Patients with Containing Recombinant Vaccinia Pros- Metastatic Prostate Cancer Advanced Cancers or Metastatic PCa tate Specific Antigen (PSA) Admixed With 57. Phase II Study of Hyperthermia and Ra- 26. Phase I/II Study of Interstitial Colloidal rV-B7.1 Plus Recombinant Fowlpox PSA diotherapy for Locally Advanced Adeno- Phosphorus P32 and Macroaggregated Vaccine, Sargramostim (GM-CSF), and carcinoma of the Prostate Albumin in Patients With Locally Recur- Interleukin-2 Versus Nilutamide Alone in 58. Phase II Study of Mitoxantrone in Com- rent Prostate Cancer That Has Failed Con- Patients With Hormone Refractory Pros- bination With Vinorelbine as First Line ventional Therapy tate Cancer Therapy in Patients With Metastatic Hor- 27. Phase I/II Study of Leuvectin in Patients 41. Phase II Study Doxorubicin and Cyclo- mone Refractory Adenocarcinoma of the With Locally Recurrent Organ Confined phosphamide With Sequential Docetaxel Prostate Prostate Cancer Following Radiotherapy in Patients With Chemotherapy Naive 59. Phase II Study of Neoadjuvant Leuvectin 28. Phase I/II Study of Mitoxantrone with Hormone Refractory Adenocarcinoma of Followed by Retropubic Prostatectomy in Filgrastim (G-CSF) Support in Patients the Prostate Patients With Stage II or III Prostate Can- with Metastatic, Hormone Refractory 42. Phase II Study of Amifostine Plus Frac- cer Prostate Cancer tionated Radiotherapy for Primary Pros- 60. Phase II Study of Nitrocamptothecin in 29. Phase I/II Study of Weekly Intravenous tate Adenocarcinoma Patients With Stage IV, Hormone Refrac- Estramustine in Combination With 43. Phase II Study of Androgen Deprivation tory Prostate Cancer Paclitaxel & Carboplatin in Patients With Followed by Three Dimensional Confor- 61. Phase II Study of Nonmyeloblative Allo- Advanced Prostate Cancer mal External Beam Radiotherapy and geneic Peripheral Blood Stem Cell and 30. Phase II Neoadjuvant Randomized Study Continued Androgen Deprivation in Pa- Donor Lymphocyte Infusions in Patients of Short and Protracted Hormonal Therapy tients w/ Adenocarcinoma of the Prostate with Refractory Metastatic Solid Tumors Prior to Radiotherapy In Patients with 44. Phase II Study of Antineoplaston A10 and 62. Phase II Study of Paclitaxel & Bryostatin Stage I-IV Localized Prostate Cancer AS2-1 Capsules for Stage III or IV Ad- 1 in Patients w/ Hormone Refractory Meta- 31. Phase II Pilot Study of Neoadjuvant enocarcinoma of the Prostate static Adenocarcinoma of the Prostate Docetaxel in Patients With High Risk 45. Phase II Study of Antineoplastons A10 63. Phase II Study of Paclitaxel Plus Stage II or III Prostate Cancer and AS2-1 Capsules with Total Androgen Estramustine in Patients with Metastatic 32. Phase II Randomized Study of Docetaxel Blockade in Patients with Stage III or IV Hormone Refractory Prostate Cancer and Estramustine Versus and Adenocarcinoma of the Prostate 64. Phase II Study of R115777 in Patients Thiotepa With Autologous Peripheral 46. Phase II Study of Antineoplastons A10 With Progressive, Metastatic, Hormone Blood Stem Cell Transplantation in Pa- and AS2-1 in Patients with Metastatic, Refractory Prostate Cancer tients With Hormone Refractory Meta- Hormone Refractory Adenocarcinoma of 65. Phase II Study of the Role of Salvage Pros- static Prostate Cancer the Prostate tatectomy after Radiation Failure in Pa- 33. Phase II Randomized Study of Docetaxel 47. Phase II Study of Antineoplastons A10 tients With Prostate Carcinoma With or Without Thalidomide in Patients and AS2-1 in Patients with Refractory 66. Phase II Study of Three-Dimensional With Androgen Independent Metastatic Stage IV Adenocarcinoma of the Prostate Conformal Radiotherapy (3D-CRT) in Prostate Cancer 48. Phase II Study of Arsenic Trioxide in Pa- Patients with Stage I or II Adenocarcinoma 34. Phase II Randomized Study of High Dose tients With Advanced Hormone Refrac- of the Prostate Ketoconazole With or Without tory Prostate Cancer 67. Phase II Study of Trastuzumab (Herceptin) Alendronate Sodium in Patients with An- 49. Phase II Study of Broxuridine in Patients and Docetaxel in Patients With Hormone drogen Independent Metastastic w/ Stage I or II Prostate Cancer Refractory, Metastatic Prostate Cancer Adenocarinoma of the Prostate 50. Phase II Study of Capecitabine in Patients 68. Phase II Study of Trastuzumab (Herceptin) 35. Phase II Randomized Study of With Metastatic Hormone Refractory in Patients w/ Progressive Androgen De- Mitoxantrone, Estramustine, and Prostate Cancer pendent and Independent Prostate Cancer Vinorelbine Versus Isotretinoin, Interferon 51. Phase II Study of Docetaxel Plus 69. Phase II Study of Vinorelbine with alfa, & Paclitaxel in Patients w/ Metastatic Estramustine in Combination With Andro- Paclitaxel in Patients with Metastatic Hor- Hormone Refractory Prostate Cancer gen Deprivation Therapy in Patients With mone-Refractory Prostate Cancer 36. Phase II Randomized Study of Paclitaxel, PSA Elevation Following Radiotherapy or 70. Phase II/III Diagnostic Study of C11- Etoposide, and Estramustine Versus Radical Prostatectomy for Early Prostate Methionine and 2-F18-Fluoro-2-deoxy-D- Ketoconazole, Doxorubicin, , Cancer Glucose (FDG) Positron Emission To- and Estramustine in Patients With Andro- 52. Phase II Study of DX-8951f in Patients mography (PET) Imaging in Patients With gen Independent Prostate Cancer w/ Hormone Refractory Prostate Cancer Progressive Prostate Cancer 37. Phase II Randomized Study of Radio- 53. Phase II Study of Endorectal MRI for 71. Phase II/III Randomized Study of therapy With or Without Vaccine Contain- Prediction of Biochemical Control of Pros- Leflunomide (SU101) With Mitoxantrone ing Recombinant Vaccinia Prostate Spe- tate Cancer Following Radiotherapy with and Prednisone Versus Mitoxantrone and cific Antigen (PSA) and rV-B7.1 Plus Androgen Suppression Prednisone Alone in Patients With Hor- Recombinant Fowlpox PSA Vaccine in 54. Phase II Study of Estramustine, Docetaxel, mone Refractory Prostate Cancer Patients With Localized Prostate Cancer and Carboplatin With Filgrastim (G-CSF) 72. Phase IIB Randomized Chemoprevention 38. Phase II Randomized Study of Recombi- Support in Patients With Hormone Refrac- Study of Eflornithine (DFMO) in Men at nant Fowlpox Prostate Specific Antigen tory Prostate Cancer High Genetic Risk For Prostate Cancer

US TOO! PCA HOTSHEET MAR / APR 2001 P. 15 (CLINICAL TRIALS - Continued from Page 15) 82. Phase III Randomized Study of 89 vs Palliative Local Radiotherapy in Mitoxantrone and Prednisone With or Patients with Hormone-Refractory Pros- 73. Phase III Randomized Adjuvant Study of Without Clodronate in Patients with Hor- tate Cancer w/ Painful Osseous Metastases Hormonal Therapy in Surgically Treated mone Refractory Metastatic PCa and Pain 93. Phase III Randomized, Double-Blind PCaPatients at High Risk of Recurrence 83. Phase III Randomized Study of Study of Radiotherapy With Versus With- 74. Phase III Randomized Comparison Study Neoadjuvant Total Androgen Suppression out Bicalutamide in Patients With PSA El- of Conformal Standard Radiotherapy Ver- and Radiotherapy in Patients w/ Interme- evation Following Radical Prostatectomy sus Conformal High Dose Radiotherapy diate Risk Adenocarcinoma of the Prostate for pT3 N0 Carcinoma of the Prostate in Addition to Neoadjuvant Androgen 84. Phase III Randomized Study of Oral Tha- 94. Phase III Study of Chemo/Hormonal Deprivation in Patients w/ Localized PCa lidomide Versus Placebo in Patients With Therapy vs Androgen Ablation Alone as 75. Phase III Randomized Study Comparing Androgen Dependent Stage IV Initial Therapy in Patients With Intermittent Versus Continuous Androgen Nonmetastatic Prostate Cancer Following Unresectable/Metastatic Adenocarcinoma Suppression for Patients with Prostate Limited Hormonal Ablation of the Prostate Specific Antigen Progression in the Clini- 85. Phase III Randomized Study of Palliative 95. Phase III Study of Long Term Adjuvant cal Absence of Distant Metastases Follow- Radiation Therapy for Bone Metastases Hormonal Treatment with LHRH Ana- ing Radiotherapy for Prostate Cancer From Breast or Prostate Cancer logue (Triptorelin) versus No Further 76. Phase III Randomized Study of Andro- 86. Phase III Randomized Study of Postop- Treatment in Patients With Locally Ad- gen Suppression and Radiotherapy With erative External Radiotherapy vs No Im- vanced Prostatic Carcinoma Treated by or Without Subsequent Paclitaxel, mediate Further Treatment in Patients with External Irradiation and a Six Month Com- Estramustine, and Etoposide in Patients pT3 pN0 Prostatic Adenocarcinoma bined Androgen Blockage w/ Localized, High Risk Prostate Cancer 87. Phase III Randomized Study of Radio- 96. Phase III Study of the Ablatherm High 77. Phase III Randomized Study of APC8015 therapy to the Prostate With or Without Intensity Focused Ultrasound Device in in Patients With Asymptomatic Metastatic Radiotherapy to the Pelvis in Patients With Patients With Stage I or II Prostate Cancer Hormone Refractory Adenocarcinoma of Stage I, II, or III Adenocarcinoma of the Following External Beam Radiotherapy the Prostate Prostate 97. Randomized Pilot Study to Evaluate Edu- 78. Phase III Randomized Study of Cyprot- 88. Phase III Randomized Study of Radio- cational Intervention and Behavioral Skills erone Acetate in Patients with Hot Flashes therapy With vs Without Neoadjuvant Training for Pain Control in Patients with Following Surgical or Chemical Castra- Flutamide Plus Goserelin or Leuprolide Recurrent or Metastatic Breast or PCa tion for Prostate Cancer. in Patients With Good Prognosis, Locally 98. Randomized Study to Evaluate the Effi- 79. Phase III Randomized Study of Intermit- Confined Adenocarcinoma of the Prostate cacy of Brief Physician-Initiated Quit- tent Versus Constant Combined Androgen 89. Phase III Randomized Study of the Ef- Smoking Strategies for Clinical Oncology Deprivation (Bicalutamide and Goserelin) fect of a Diet Low in Fat and High in Soy, Settings in Patients With Stage IV Prostate Cancer Fruits, Vegetables, Green Tea, Vitamin E, 99. Study of Androgen Ablation and Bone Responsive to Such Therapy & Fiber on PSA Levels in Pts With PCa Resorption in Patients With or Without 80. Phase III Randomized Study of Low 90. Phase III Randomized Study of Total Bone Metastases Secondary to PCa Molecular Weight Heparin (Dalteparin) Androgen Blockade With or Without Pel- 100. Study of Androgen Receptor Mutations Plus Standard Therapy Versus Standard vic Irradiation in Patients w/ Stage T3-4, in Hormone Refractory Prostate Cancer Therapy Alone in Patients with Advanced N0, M0 Adenocarcinoma of the Prostate 101. Supportive-Expressive Group Therapy Cancer 91. Phase III Randomized Study of Weekly for Men with Stage I/II Prostate Cancer 81. Phase III Randomized Study of Low- vs Doxorubicin in Patients with Metastatic, Intermediate- vs High-Dose Suramin for Hormone-Refractory Prostate Cancer VISIT WWW.USTOO.ORG Advanced Hormone-Refractory PCa 92. Phase III Randomized Trial of Strontium- FOR LINKS TO CURRENT CLINICAL TRIALS!

Us Too! International is a charitable volunteer driven organization funded by donations from individuals, memorial gifts, and grants from agencies, medical professionals, pharmaceutical and other companies. Contribute today!

Name: Company: ______Address:______City: ______State: _____ ZIP: ______Phone: ( ) ______Fax: ( ) ______eMail:______Please accept my enclosed tax-deductible donation to Us Too! a not-for-profit 501(c)(3) organization. Amount ___$25 ___$50 ___$75 ___$100 Other: $ ______Check # Visa/Master Card # ______Expiration Date: /

Signature ______Us Too! International, Inc., 5003 Fairview Ave., Downers Grove, IL 60515